CN101102797A

CN101102797A - Composition for external use

Info

Publication number: CN101102797A
Application number: CNA2006800019317A
Authority: CN
Inventors: 原田绫子; 本间阳一; 阿部正通
Original assignee: Rohto Pharmaceutical Co Ltd
Current assignee: Rohto Pharmaceutical Co Ltd
Priority date: 2005-01-07
Filing date: 2006-01-06
Publication date: 2008-01-09

Abstract

An object of the present invention is to provide a composition for external use in which the percutaneous absorbability of vitamin A, vitamin A derivative(s), vitamin C, specific vitamin C derivative(s), xanthine derivative(s), ubiquinone(s) and/or hyaluronic acid is improved. The composition for external use is prepared by blending (i) a phospholipid and (ii) a mono- or oligo-glycol ether, together with (iv) at least one bioactive component selected from the group consisting of hyaluronic acid, hyaluronic acid derivatives, vitamin A, vitamin A derivatives, vitamin C, specific vitamin C derivatives, xanthine derivatives, ubiquinones, and salts thereof.

Description

Topical composition

Technical field

The present invention relates to a kind of topical composition that can improve the percutaneous absorbability of physiologically active ingredient.

Background technology

Be applicable to the topical composition of skin or mucosa, various dosage forms such as patch, ointment, cream, lotion, solid preparation are arranged.Topical composition can be applicable to the skin affected part corresponding to the form of its dosage form, but owing to there is the horny layer of the invasion that stops the foreign body that comes from the outside, the Transdermal absorption of the physiologically active ingredient in the topical composition is reduced.Therefore, for topical composition, it is just very important to make contained physiologically active ingredient effectively be impregnated into skin.

In the past, in order to promote Transdermal absorption, various researchs have been carried out, for example, as the external preparation that improves percutaneous absorbability, reported the Liposomal formulation (patent documentation 1) that contains lecithin and hydrophilic nonionic surfactant, contained the topical composition (patent documentation 2) of phospholipid and specific polyhydric alcohol etc.

On the other hand, phospholipid is present in the natural animal-plants such as Semen sojae atricolor, egg yolk, and it nearly all is the higher composition of safety that can be used for food, can be mixed in also that medicine or cosmetic material use.For this phospholipid, known have surface activity effect and moisture retention, and know if sneak into the Transdermal absorption that topical composition promotes physiologically active ingredient.But, based on the percutaneous absorbability of the physiologically active ingredient of the effect of phospholipid, fail to be met, need further to improve the Transdermal absorption facilitation.In addition, but do not know at present can reach the effect of the Transdermal absorption of physiologically active ingredient by combination phospholipid and alcohol ether.

In addition, for the vitamin A in the physiologically active ingredient that is mixed in the topical composition, vitamin C, xanthine derivative, ubiquinone and hyaluronic acid, it is reported various useful physiologically actives.Yet for the percutaneous absorbability that can improve these physiologically active ingredients, the prescription that plays the desired topical composition that useful effect was fit to is unclear.

Particularly for hyaluronic acid, known its molecular weight is several thousand～5,000,000 very big, even transdermal is suitable for, is difficult to be impregnated into skin inside but also only rest on epidermis.For this reason, the hyaluronic topical composition that contains in the past has the shortcoming that can not fully obtain based on hyaluronic useful physiological action.

Patent documentation 1: Japanese kokai publication sho 62-95134 communique

Patent documentation 2: Japanese kokai publication hei 10-194994 communique

Summary of the invention

The object of the present invention is to provide a kind of good topical composition of percutaneous absorbability of physiologically active ingredient.The present invention also aims to provide a kind of topical composition, the percutaneous absorbability of its vitamin A, vitamin A derivative, vitamin C, specific vitamin C derivatives, xanthine derivative, ubiquinone, hyaluronic acid or derivatives of hyaluronic acids is good.

Discoveries such as the inventor contain (i) phospholipid and the (ii) topical composition of list or low diol ether by use, can solve above-mentioned problem.Particularly, find to contain (i) phospholipid and the (ii) topical composition of list or low diol ether, can improve the (iii) percutaneous absorbability of physiologically active ingredient with special ratios.And, by to contain (iv) vitamin A, vitamin A derivative, vitamin C, specific vitamin C derivatives, xanthine derivative, ubiquinone and/or hyaluronic topical composition as physiologically active ingredient in, mix (i) phospholipid and (ii) list or low diol ether, significantly improve the Transdermal absorption efficient of these specific physiologically active ingredients.Based on these understanding, finished the present invention by further improveing repeatedly.

That is, the invention provides the topical composition of following announcement:

1-1. topical composition is characterized in that, contains (i) phospholipid and (ii) list or low diol ether, with respect to the total amount of topical composition, contains (ii) list or low diol ether with the ratio more than the 22 weight %.

Item 1-2. such as the described topical composition of item 1-1 also contain (iii) physiologically active ingredient.

1-3. such as the described topical composition of item 1-1, wherein, (i) phospholipid is to be selected from least a in phosphoglyceride and the sphingomyelinase.

Item 1-4. such as the described topical composition of item 1-1, wherein, (i) phospholipid is a hydrogenated phospholipid matter.

Item 1-5. such as the described topical composition of item 1-1, wherein, (i) phospholipid is non-hydrogenation phospholipid.

Item 1-6. such as the described topical composition of item 1-1, wherein, (i) phospholipid is a lecithin.

Item 1-7. such as the described topical composition of item 1-6, wherein, the iodine number of lecithin is 10～50.

Item 1-8. such as the described topical composition of item 1-1, wherein, (ii) list or low diol ether are the chemical compound of following general formula (1) expression.

R ₁-O(A-O) _n-R ₂ (1)

(in the formula, R ₁And R ₂Identical or different, be the alkyl of carbon number 1～6, thiazolinyl, aryl, acetyl group or the hydrogen atom of carbon number 2～6, wherein, R ₁And R ₂At least one side be the alkyl of carbon number 1～6, the thiazolinyl or the aryl of carbon number 2～6; A represents the alkylidene of carbon number 2～4; N represents 1～4 integer.)

Item 1-9. such as the described topical composition of item 1-1, wherein, (ii) list or low diol ether are to be selected from least a in ethylene glycol mono-ether, ethylene glycol diether, diethylene glycol monoether, diethylene glycol diether, triethylene glycol monoether, triethylene glycol diether, TEG monoether, TEG diether, propylene glycol monoether, propylene glycol diether, dipropylene glycol monoether, dipropylene glycol diether, tripropylene glycol monoether, tripropylene glycol diether, butanediol monoether and the butanediol diether.

1-10. such as the described topical composition of item 1-1 with respect to the total amount of topical composition, contain (i) phospholipid with the ratio of 0.01～15 weight %.

Item 1-11. such as the described topical composition of item 1-1, wherein, (i) phospholipid is hydrolecithin and/or non-hydrolecithin.

Item 1-12. such as the described topical composition of item 1-2, wherein, (iii) physiologically active ingredient be selected from vitamins, whitening agent, anti-wrinkle agent, analgesic agent, antifungal, steroid dose, educate a mao agent, at least a in weight reducing agent, local anesthetic, pruritus, antibacterial, antiviral agent, keratolytic, wetting agent, astringent, antioxidant and the hair inhibitor.

Item 1-13. such as the described topical composition of item 1-1 are the liquid crystal type topical composition.

Item 1-14. such as the described topical composition of item 1-1 are the micro-emulsion type topical composition.

Item 1-15. such as the described topical composition of item 1-1 are lipid build topical composition.

Item 1-16. such as the described topical composition of item 1-1 are composite medicine.

Item 1-17. such as the described topical composition of item 1-1 are cosmetic material.

In addition, the present invention also provides the topical composition of following announcement:

Item 2-1. topical composition is characterized in that, with respect to the total amount of topical composition, contains (i) phospholipid of 0.01～8 weight % and (ii) list or the low diol ether of 0.01～6.5 weight %.

Item 2-2. such as the described topical composition of item 2-1 also contain (iii) physiologically active ingredient.

2-3. such as the described topical composition of item 2-1, wherein, (i) phospholipid is to be selected from least a in phosphoglyceride and the sphingomyelinase.

Item 2-4. such as the described topical composition of item 2-1, wherein, (i) phospholipid is a hydrogenated phospholipid matter.

Item 2-5. such as the described topical composition of item 2-1, wherein, (i) phospholipid is non-hydrogenation phospholipid.

Item 2-6. such as the described topical composition of item 2-1, wherein, (i) phospholipid is a lecithin.

Item 2-7. such as the described topical composition of item 2-6, wherein, the iodine number of lecithin is 10～50.

Item 2-8. such as the described topical composition of item 2-1, wherein, (ii) list or low diol ether are the chemical compound of following general formula (1) expression.

R ₁-O(A-O) _n-R ₂ (1)

Item 2-9. such as the described topical composition of item 2-1, wherein, (ii) list or low diol ether are to be selected from least a in ethylene glycol mono-ether, ethylene glycol diether, diethylene glycol monoether, diethylene glycol diether, triethylene glycol monoether, triethylene glycol diether, TEG monoether, TEG diether, propylene glycol monoether, propylene glycol diether, dipropylene glycol monoether, dipropylene glycol diether, tripropylene glycol monoether, tripropylene glycol diether, butanediol monoether and the butanediol diether.

2-10. such as the described topical composition of item 2-1 with respect to (i) phospholipid 1 weight portion, contain (ii) list or low diol ether with the ratio of 0.01～70 weight portion.

Item 2-11. such as the described topical composition of item 2-1, wherein, (i) phospholipid is hydrogenated phospholipid matter and/or non-hydrogenated phospholipid.

Item 2-12. such as the described topical composition of item 2-2, wherein, (iii) physiologically active ingredient be selected from vitamins, whitening agent, anti-wrinkle agent, analgesic agent, antifungal, steroid dose, educate a mao agent, at least a in weight reducing agent, local anesthetic, pruritus, antibacterial, antiviral agent, keratolytic, wetting agent, astringent, antioxidant and the hair inhibitor.

Item 2-13. such as the described topical composition of item 2-1 are the liquid crystal type topical composition.

Item 2-14. such as the described topical composition of item 2-1 are the micro-emulsion type topical composition.

Item 2-15. such as the described topical composition of item 2-1 are lipid build topical composition.

Item 2-16. such as the described topical composition of item 2-1 are composite medicine.

Item 2-17. such as the described topical composition of item 2-1 are cosmetic material.

Item 3-1. topical composition contains

(i) phospholipid,

(ii) list or low diol ether, and

(iv) be selected from least a physiologically active ingredient in salt, hydroascorbic acid, ascorbate glucoside, ascorbyl stearate, L-Vitamin C dipalmitate and/or VC-IP, xanthine derivative, ubiquinone and their salt of hyaluronic acid, derivatives of hyaluronic acids, vitamin A, vitamin A derivative, ascorbic acid, ascorbic acid.

3-2. such as the described topical composition of item 3-1, wherein, (i) phospholipid is to be selected from least a in phosphoglyceride and the sphingomyelinase.

Item 3-3. such as the described topical composition of item 3-1, wherein, (i) phospholipid is a hydrogenated phospholipid matter.

Item 3-4. such as the described topical composition of item 3-1, wherein, (i) phospholipid is non-hydrogenation phospholipid.

Item 3-5. such as the described topical composition of item 3-1, wherein, (i) phospholipid is a lecithin.

Item 3-6. such as the described topical composition of item 3-5, wherein, the iodine number of lecithin is 10～50.

3-7. such as the described topical composition of item 3-1 with respect to the total amount of topical composition, contain (i) phospholipid with the ratio of 0.01～15 weight %.

Item 3-8. such as the described topical composition of item 3-1, wherein, (ii) list or low diol ether are the chemical compound of following general formula (1) expression.

R ₁-O(A-O) _n-R ₂ (1)

Item 3-9. such as the described topical composition of item 3-1, wherein, (ii) list or low diol ether are to be selected from least a in ethylene glycol mono-ether, ethylene glycol diether, diethylene glycol monoether, diethylene glycol diether, triethylene glycol monoether, triethylene glycol diether, TEG monoether, TEG diether, propylene glycol monoether, propylene glycol diether, dipropylene glycol monoether, dipropylene glycol diether, tripropylene glycol monoether, tripropylene glycol diether, butanediol monoether and the butanediol diether.

3-10. such as the described topical composition of item 3-1 with respect to the total amount of topical composition, contain (ii) list or low diol ether with the ratio of 0.01～80 weight %.

Item 3-11. such as the described topical composition of item 3-1, wherein, (i) phospholipid is hydrogenated phospholipid matter and/or non-hydrogenated phospholipid.

3-12. such as the described topical composition of item 3-1, wherein, (iv) physiologically active ingredient is to be selected from least a in hyaluronic acid, hyaluronan and their salt.

Item 3-13. such as the described topical composition of item 3-1, wherein, (iv) physiologically active ingredient is to be selected from least a in retinol, retinyl acetate, retinol cetylate, retinal, tretinoin, tretinoin methyl ester, tretinoin ethyl ester, tretinoin retinol ester, vitamin A fatty acid ester, d-δ-Wei A fertility alcohol ester, α-Wei A fertility alcohol ester and β-Wei A fertility alcohol ester.

Item 3-14. such as the described topical composition of item 3-1, wherein, (iv) physiologically active ingredient is at least a in salt, hydroascorbic acid, ascorbate glucoside, ascorbyl stearate, L-Vitamin C dipalmitate and the VC-IP that is selected from ascorbic acid, ascorbic acid.

Item 3-15. such as the described topical composition of item 3-1, wherein, (iv) physiologically active ingredient is an at least a xanthine derivative in caffeine, aminophylline, theophylline, Oxtriphylline, glycerol dish alkali, two isobutyl aminobenzoic acyl-oxygen propyl group theophylline, theobromine, diprophylline, proxyphylline and the pentoxifylline.

Item 3-16. such as the described topical composition of item 3-1, wherein, (iv) physiologically active ingredient is at least a ubiquinone that is selected among Coenzyme Qq6, Q7, Q8, Q9 and the Q10.

Item 3-17. such as the described topical composition of item 3-1 are the liquid crystal type topical composition.

Item 3-18. such as the described topical composition of item 3-1 are the micro-emulsion type topical composition.

Item 3-19. such as the described topical composition of item 3-1 are lipid build topical composition.

Item 3-20. such as the described topical composition of item 3-1 are composite medicine.

Item 3-21. such as the described topical composition of item 3-1 are cosmetic material.

In addition, the invention provides the method for the percutaneous absorbability of improving physiologically active ingredient of following announcement:

The 4. 1 kinds (iii) improvement methods of the percutaneous absorbability of physiologically active ingredient, it is characterized in that, in containing the topical composition of (iii) physiologically active ingredient, with respect to the total amount of topical composition, contain (i) phospholipid and contain (ii) list or low diol ether with the ratio of 0.01～6.5 weight % with the ratio of 0.01～8 weight %.

The 5. 1 kinds (iii) improvement methods of the percutaneous absorbability of physiologically active ingredient, it is characterized in that, in containing the topical composition of (iii) physiologically active ingredient, with respect to the total amount of topical composition, contain (i) phospholipid and contain (ii) list or low diol ether with the ratio of 0.01～6.5 weight % with the ratio of 0.01～8 weight %.

The improvement method of the percutaneous absorbability of 6. 1 kinds of aforementioned (iv) physiologically active ingredients of item, it is characterized in that, in containing the topical composition that (iv) is selected from least a physiologically active ingredient in hyaluronic acid, derivatives of hyaluronic acids, vitamin A, vitamin A derivative, ascorbic acid, hydroascorbic acid, ascorbate glucoside, ascorbyl stearate, L-Vitamin C dipalmitate and/or VC-IP, xanthine derivative, ubiquinone and their salt, contain (i) phospholipid and (ii) list or low diol ether.

In addition, the present invention also provides the application of the mode of following announcement:

7. contain (i) phospholipid and (ii) list or low diol ether, total amount with respect to topical composition, contain the topical composition of (ii) list or low diol ether with the ratio more than the 22 weight %, the application in promoting the Transdermal absorption of (iii) physiologically active ingredient.

8. contain (i) phospholipid and (ii) list or low diol ether, total amount with respect to topical composition, contain the topical composition of (ii) list or low diol ether with the ratio more than the 22 weight %, improve application in the preparation of the (iii) Transdermal absorption of physiologically active ingredient in manufacturing.

9. total amounts with respect to topical composition contain (i) phospholipid and the (ii) list of 0.01～6.5 weight % or the topical composition of low diol ether of 0.01～8 weight %, the application in promoting the Transdermal absorption of (iii) physiologically active ingredient.

Item 10. total amounts with respect to topical composition, (i) phospholipid and the (ii) list of 0.01～6.5 weight % or the topical composition of low diol ether that contain 0.01～8 weight % improve application in the preparation of the (iii) Transdermal absorption of physiologically active ingredient in manufacturing.

11. contain (i) phospholipid and the (ii) topical composition of list or low diol ether, (iv) are selected from application in the Transdermal absorption of at least a physiologically active ingredient in hyaluronic acid, derivatives of hyaluronic acids, vitamin A, vitamin A derivative, ascorbic acid, hydroascorbic acid, ascorbate glucoside, ascorbyl stearate, L-Vitamin C dipalmitate and/or VC-IP, xanthine derivative, ubiquinone and their salt in promotion.

12. contain (i) phospholipid and the (ii) topical composition of list or low diol ether, the application in the preparation of making the Transdermal absorption that improvement (iv) is selected from least a physiologically active ingredient in hyaluronic acid, derivatives of hyaluronic acids, vitamin A, vitamin A derivative, ascorbic acid, hydroascorbic acid, ascorbate glucoside, ascorbyl stearate, L-Vitamin C dipalmitate and/or VC-IP, xanthine derivative, ubiquinone and their salt.

The specific embodiment

A. topical composition

Topical composition of the present invention contains (i) phospholipid and (ii) list or low diol ether.Below, describe in detail for the phospholipid that uses in the present invention and list or low diol ether.

1. phospholipid

Phospholipid is not particularly limited so long as allow blended getting final product in the external compositions.Particularly, can enumerate phosphoglyceride, sphingomyelinase etc.

Phosphoglyceride is the lipid with glyceric acid skeleton, have as the long-chain fatty acid of lipophilic group and glycerol carry out ester after combining, long-chain alcohol and glycerol carry out ether after combining or long-chain fatty acid and glycerol carry out vinyl ethers after combining.Particularly, can enumerate phosphatidylcholine, PHOSPHATIDYL ETHANOLAMINE, Phosphatidylserine, phosphatidylinositols, polyphosphoinositide, phosphatidyl glycerol, diphosphatidylglycerol (cuorin), phosphatidic acid, LYSO-PHOSPHATIDYLCHOLINE LYSOPC, lysophosphatidyl ethanolamine, hemolytic phosphatidylserine, hemolytic phosphatidyl inositol, lysophosphatidyl glycerol, lysophosphatidic acid etc.

Sphingomyelins is on the amino of the C-2 position of sphingol or phytosphingosine, the long chain fatty acids amides combination, and the hydroxyl Phosphoric acid or phosphonic acid in the C-1 position carries out the bonded phospholipid of phosphate ester.As sphingomyelins, particularly, can enumerate the ceramide-1-phosphoric acid derivatives of sphingomyelin etc.; Ceramide-1-phosphonate derivatives such as ceramide amino-ethyl phosphonic acids.

In these phospholipid, be preferably sphingomyelins, especially preferably can enumerate phosphatidylcholine, PHOSPHATIDYL ETHANOLAMINE, phosphatidyl glycerol.

In addition, being used for phospholipid of the present invention, can be the natural origin of driven plant extract, purification, also can be chemosynthesis, can also implement processing such as hydrogenation treatment or hydroxylating processing.In addition, also can use commercially available product.As the phospholipid of natural origin, known conduct is from the lecithin of the purification thing of Semen sojae atricolor or egg yolk etc.In the present invention, as phospholipid, especially preferably use lecithin.

Lecithin can be non-hydrolecithin, hydrolecithin, hydroxylated lecithin etc.Be preferably non-hydrolecithin or hydrolecithin, preferred especially non-hydrolecithin.Preferred partial hydrogenation in the hydrolecithin, degree of hydrogenation is low more just preferred more.In addition, the iodine number of lecithin is generally 10～50, is preferably 20～45, is preferably 30～45 especially.

2. list or low diol ether

List or low diol ether be single or the hydroxyl of low alkylene alcohol single or two by the chemical compound of etherificate.If the situation of low diol ether can be the part that is made of low aklylene glycol two or more aklylene glycols.List that uses among the present invention or low diol ether can blended limits in the external compositions, is not particularly limited, and as its example that is fit to, but the chemical compound that example is represented with following general formula (1).

R ₁-O(A-O) _n-R ₂ (1)

In general formula (1), R ₁And R ₂Identical or different, be the alkyl of carbon number 1～6, thiazolinyl, aryl, acetyl group or the hydrogen atom of carbon number 2～6, wherein, R ₁And R ₂At least one side be the alkyl of carbon number 1～6, the thiazolinyl or the aryl of carbon number 2～6.Alkyl as carbon number 1～6, for a straight chain shape or a catenate alkyl that constitutes by carbon number 1～6, can enumerate methyl, ethyl, n-pro-pyl, isopropyl, normal-butyl, isobutyl group, the tert-butyl group, sec-butyl, n-pentyl, neopentyl, n-hexyl, isohesyl, 3-methyl amyl etc.

As the thiazolinyl of carbon number 2～6, particularly, can enumerate vinyl, pi-allyl, hexadienyl etc.

As aryl, particularly, phenyl, tolyl, xylyl, naphthyl etc. are arranged.

In addition, in general formula (1), A represents the alkylidene of carbon number 2～4.As the alkylidene of carbon number 2～4, particularly, can enumerate ethylidene, trimethylene, tetramethylene etc.

In addition, in general formula (1), n is 1～4 integer, the degree of polymerization of expression alcohol.

As employed list among the present invention or low diol ether, can enumerate ethylene glycol mono-ether, ethylene glycol diether, diethylene glycol monoether, diethylene glycol diether, triethylene glycol monoether, triethylene glycol diether, TEG monoether, TEG diether, propylene glycol monoether, propylene glycol diether, dipropylene glycol monoether, dipropylene glycol diether, tripropylene glycol monoether, tripropylene glycol diether, butanediol monoether, butanediol diether etc.

Object lesson as list or low diol ether, can enumerate, the glycol monomethyl vinyl ethers, ethylene glycol monomethyl ether, the glycol monomethyl n-propyl ether, the glycol monomethyl isopropyl ether, the glycol monomethyl n-butyl ether, the glycol monomethyl isobutyl ether, the glycol monomethyl tertbutyl ether, glycol monomethyl-2-methyl amylether, glycol monomethyl n-hexyl ether, glycol monomethyl-2,4-hexadienyl ether, glycol monomethyl-2,6,8-trimethyl-4-nonyl ethers, glycol monomethyl phenyl ether and glycol monomethyl cresyl ether, the ethylene glycol monomethyl ether acetate, ethylene glycol monomethyl ether acetate, ethylene glycol mono-ethers such as glycol monomethyl n-butyl ether acetas; Ethylene glycol diether such as ethylene glycol dimethyl ether and ethylene glycol bisthioglycolate ethylether; Diethylene glycol monoethers such as diethylene glycol monomethyl ether, TC (below be labeled as " ethoxydiglycol "), diethylene glycol list n-propyl ether, diethylene glycol list n-butyl ether, diethylene glycol list isobutyl ether, diethylene glycol list n-hexyl ether, diethylene glycol monomethyl phenyl ether, diethylene glycol list ethylphenyl ether acetic acid ester, diethylene glycol list n-butyl ether acetas; Diethylene glycol diether such as diethylene glycol dimethyl ether and diethylene glycol divinyl ether; Triethylene glycol monoethers such as triethylene glycol monomethyl ether, triethylene glycol list ethylether, triethylene glycol list n-butyl ether and triethylene glycol mono-vinyl ethylether; Triethylene glycol diether such as triethylene glycol dimethyl ether, triethylene glycol divinyl ether; TEG monoethers such as TEG list phenyl ether; TEG diether such as TEG Anaesthetie Ether; Low diol monoethers such as low diol monomethyl ether; Propylene glycol monoethers such as propylene glycol monomethyl ether, propylene glycol list ethylether, propylene glycol list n-propyl ether, propylene glycol monoisopropyl ether, propylene glycol list n-butyl ether, propylene glycol list isobutyl ether, propylene glycol mono allyl ether, propylene glycol list phenyl ether and propylene glycol monomethyl ether; Propylene glycol diether such as propylene glycol dimethyl ether, propylene glycol Anaesthetie Ether, propylene glycol di ether, propylene glycol Di Iso Propyl Ether, propylene glycol di-n-butyl ether, propylene glycol diisobutyl ether, propylene glycol diallyl ether and propylene glycol diphenyl ether; Dipropylene glycol monoethers such as dihydroxypropane single-ethyl ether, dipropylene glycol list n-butyl ether, dipropylene glycol list isobutyl ether and dipropylene glycol allyl ether; Dipropylene glycol diether such as dipropylene glycol Anaesthetie Ether, dipropylene glycol di-n-butyl ether, dipropylene glycol Di Iso Propyl Ether and dipropylene glycol allyl ether; Tripropylene glycol monoethers such as tripropylene glycol monomethyl ether, tripropylene glycol list ethylether, tripropylene glycol list n-butyl ether, tripropylene glycol list isobutyl ether and tripropylene glycol mono allyl ether; Tripropylene glycol diether such as tripropylene glycol dimethyl ether, tripropylene glycol Anaesthetie Ether, tripropylene glycol di-n-butyl ether, tripropylene glycol diisobutyl ether and tripropylene glycol diallyl ether; Low propylene glycol monoethers such as low propylene glycol single-butyl ether; Butanediol monoethers such as butanediol monomethyl ether, butanediol list ethylether and butanediol list n-butyl ether; Butanediol diether such as butanediol dimethyl ether, butanediol Anaesthetie Ether and butanediol di-n-butyl ether etc.

In the present invention, as preferred list or low diol ether, can be set forth in the middle A of general formula (1) is the chemical compound of the alkylidene of carbon number 2 or 3.As such chemical compound, particularly, can enumerate ethylene glycol mono-ether, ethylene glycol diether, diethylene glycol monoether, diethylene glycol diether, triethylene glycol monoether, TEG monoether, TEG diether, low diol monoether, propylene glycol monoether, propylene glycol diether, dipropylene glycol monoether, dipropylene glycol diether and tripropylene glycol monoether etc.

In general formula (1), as A is the chemical compound of the alkylidene of carbon number 2 or 3, more specifically, can enumerate the glycol monomethyl vinyl Ether, ethylene glycol monomethyl ether, the glycol monomethyl n-propyl ether, the glycol monomethyl isopropyl ether, the glycol monomethyl n-butyl ether, the glycol monomethyl isobutyl ether, the glycol monomethyl tertbutyl ether, glycol monomethyl-2-methyl amylether, ethylene glycol dimethyl ether, the ethylene glycol bisthioglycolate ethylether, diethylene glycol monomethyl ether, TC, diethylene glycol list n-propyl ether, diethylene glycol list n-butyl ether, diethylene glycol list isobutyl ether, diethylene glycol list n-hexyl ether, diethylene glycol monomethyl phenyl ether, diethylene glycol dimethyl ether, the diethylene glycol divinyl ether, the diethylene glycol ethyl vinyl ether, the triethylene glycol monomethyl ether, triethylene glycol list ethylether, triethylene glycol list n-butyl ether, triethylene glycol mono-vinyl ethylether, TEG list phenyl ether, the TEG Anaesthetie Ether, the low diol monomethyl ether, propylene glycol monomethyl ether, propylene glycol list ethylether, propylene glycol list n-propyl ether, the propylene glycol monoisopropyl ether, propylene glycol list n-butyl ether, propylene glycol phenyl ether, propylene glycol monomethyl ether, the propylene glycol dimethyl ether, the propylene glycol Anaesthetie Ether, propylene glycol di ether, the propylene glycol Di Iso Propyl Ether, the propylene glycol di-n-butyl ether, propylene glycol diisobutyl ether, the propylene glycol diallyl ether, the propylene glycol diphenyl ether, dihydroxypropane single-ethyl ether, dipropylene glycol list n-butyl ether, dipropylene glycol Anaesthetie Ether and dipropylene glycol di-n-butyl ether, the dipropylene glycol Di Iso Propyl Ether, the dipropylene glycol mono allyl ether, the tripropylene glycol monomethyl ether, tripropylene glycol list ethylether and tripropylene glycol list n-butyl ether.

Among the present invention,, can be set forth in R in the general formula (1) as further preferred list or low diol ether ₁, R ₂Either party be the alkyl of carbon number 1～6, an other side is a hydrogen atom; A is the alkylidene of carbon number 2 or 3; N is 1 or 2 chemical compound.As such chemical compound, particularly, as the further preferred ethylene glycol mono-ether of alcohol ether, diethylene glycol monoether, propylene glycol monoether, dipropylene glycol monoether.

Among the present invention,, can be set forth in R in the general formula (1) as particularly preferred list or low diol ether ₁, R ₂Either party be the alkyl of carbon number 1～3, an other side is a hydrogen atom; A is the alkylidene of carbon number 2 or 3; N is 1 or 2 chemical compound.As such chemical compound, particularly, can enumerate glycol monomethyl methyl ether, ethylene glycol monomethyl ether, glycol monomethyl propyl ether, diethylene glycol monomethyl ether, TC, diethylene glycol list n-propyl ether, propylene glycol list ethylether, propylene glycol list n-propyl ether, dihydroxypropane single-ethyl ether, dipropylene glycol list n-propyl ether.Wherein, TC most preferably.

3. combination (i) phospholipid and (ii) list or low diol ether and (iii) physiologically active ingredient Embodiment

The present invention is containing (i) phospholipid and (ii) list or low diol ether and (iii) in the topical composition of physiologically active ingredient, (1) mixed proportion with above-mentioned (ii) list or low diol ether is set at more than the 22 weight %, (2) above-mentioned (i) phospholipid is set at 0.01～8 weight % and (ii) list or low diol ether are set at 0.01～6.5 weight %, perhaps (3) select (iv) specific physiologically active ingredient to mix, thus, can improve the percutaneous absorbability of the physiologically active ingredient in the topical composition.Below, 3 embodiments are described in detail in detail respectively.

(1) embodiment 1

First, the invention provides a kind of topical composition, it is by containing (i) phospholipid and (ii) list or low diol ether, and with this (ii) the mixed proportion of list or low diol ether be set in particular range, can further improve the percutaneous absorbability of contained (iii) physiologically active ingredient.

Promptly, the present invention is a kind of topical composition (below be labeled as topical composition 1), it is characterized in that, contains (i) phospholipid and (ii) list or low diol ether, with respect to the total amount of topical composition, contain (ii) list or low diol ether with the ratio more than the 22 weight %.

Mixed proportion as (i) phospholipid in the topical composition 1 of the present invention is not particularly limited, and with respect to the total amount of this topical composition 1, is generally 0.01～15 weight %, is preferably 0.05～10 weight %, is preferably 0.1～8 weight % especially.

In addition, the (ii) list in topical composition 1 of the present invention or the mixed proportion of low diol ether are more than the 22 weight % with respect to the total amount of this topical composition 1.(ii) the mixed proportion of list or low diol ether is preferably 25～80 weight %, more preferably 30～70 weight %.By will be (ii) the mixed proportion of list or low diol ether be set in such scope, can make more effectively Transdermal absorption of physiologically active ingredient.

In topical composition 1 of the present invention, with respect to the mixed proportion of the (ii) list or the low diol ether of (i) phospholipid, satisfy above-mentioned (i) phospholipid and (ii) the scope of the mixed proportion separately of list or low diol ether suitably set.Particularly, can enumerate with respect to (i) phospholipid 1 weight portion, (ii) list or low diol ether are generally 1～300 weight portion, are preferably 2～100 weight portions, are preferably the ratio of 3～50 weight portions especially.

Topical composition 1 of the present invention except above-mentioned (i) phospholipid and (ii) list or low diol ether, also contains (iii) physiologically active ingredient.Be mixed in the (iii) physiologically active ingredient of topical composition 1 of the present invention,, can be applicable to transdermal, given play to desired physiologically active, then be not particularly limited if can be mixed in topical composition.Can enumerate, vitamins, whitening agent, anti-wrinkle agent, analgesic agent, antifungal, steroid dose, educate a mao agent, weight reducing agent, local anesthetic, pruritus, antibacterial, antiviral agent, keratolytic, wetting agent, astringent, antioxidant and hair inhibitor etc.Wherein, preferred vitamin class (particularly retinoid and water-soluble vitamin c class), whitening agent, anti-wrinkle agent, analgesic agent, antifungal, steroid dose, educate mao agent and the weight reducing agent, more preferably retinoid, water-soluble vitamin c class, anti-wrinkle agent and weight reducing agent.These physiologically active ingredients can make up more than a kind or 2 kinds and use.

Be blended in the mixed proportion of the (iii) physiologically active ingredient in the topical composition 1 of the present invention, can suitably set according to the kind of physiologically active ingredient, the form of this topical composition 1 etc., common total amount with respect to topical composition 1, (iii) the total amount of physiologically active ingredient is 0.001～50 weight %, preferred 0.005～40 weight % is more preferably the ratio of 0.01～30 weight %.

(iii) the concrete example of the kind of physiologically active ingredient and mixed proportion thereof is as follows more specifically, but is not limited to this.

As above-mentioned vitamins, can enumerate retinol, retinyl acetate, retinol cetylate, retinal, tretinoin, tretinoin methyl ester, tretinoin ethyl ester, tretinoin retinol ester, vitamin A fatty acid ester, d-δ-Wei A fertility alcohol ester, α-Wei A fertility alcohol ester, β-retinoids such as Wei A fertility alcohol ester; Caritols such as beta-carotene, alpha-carotene, gamma carotene, δ-carotene, lycopene, cryptoxanthin, kryptoxanthin, farnoquinone; The vitamin E class of succinic acid dl-alpha-tocopherol, succinic acid dl-alpha-tocopherol calcium etc.; Vitamin B2 classes such as riboflavin, flavin mononucleotide (FMN), flavin adenine dinucleotide (FAD), Riboflavine Tertrabutyrate, Riboflavin Tetrabutyrate, riboflavin-5 '-phosphate ester sodium, riboflavin four nicotinates; Nicotinic acid classes such as methyl nicotinate, nicotinic acid, nicotinamide; Vitamin c class such as ascorbyl stearate, L-Vitamin C dipalmitate, hydroascorbic acid, ascorbic acid phosphoric acid esters sodium, magnesium L-ascorbyl-2-phosphate, magnesium ascorbyl phosphate, sodium ascorbyl phosphate, ascorbate glucoside; Vitamin D classes such as methyl hersperidin, vitamin D2, vitamin D3; Vitamin K such as phylloquinone, echinenone class; Vitamin B1 classes such as gamma oryzanol, vitamin B1, vitamin b1 hydrochloride, thiamine hydrochloride, spermaceti thiamine hydrochloride, Hydrogen thiocyanate thiamine salt, Laurel thiamine salt, thiamine nitrate, thiamine monophosphate salt, thiamine lysinate, thiamine triphosphoric acid salt, thiamine monophosphate ester phosphate, thiamine monophosphate ester, thiamine bisphosphate, thiamine bisphosphate hydrochlorate, thiamine triphosphoric acid ester, thiamine triphosphoric acid ester monophosphate; Vitamin B6 classes such as pyridoxine hydrochloride, acetic acid pyridoxol, pyridoxal hydrochloride, 5 '-pyridoxal 5-phosphate, hydrochloric acid pyridoxamine; Vitamin B12 classes such as cobalamin, hydroxocobalamine, cobamamide; Folic acid such as folic acid, pteroylglutamic acid class; Pantothenic acid classes such as pantothenic acid, calcium pantothenate, pantothenylol (panthenol), D-パ Application テサイ Application, D-pantethine, coenzyme A, pantothenylol ether; Biotin classes such as biotin, PVC オチシ Application; The vitaminoid action factors such as carnitine, ferulic acid, alpha-lipoic acid, orotic acid etc.

The mixed proportion of employed vitamins is not particularly limited among the present invention, can consider that use feeling or physiologically active effect suitably set.For example, the mixed proportion of this vitamins is generally 0.1～30 weight % with respect to the total amount of topical composition 1, is preferably 0.5～25 weight %, is preferably 1～20 weight % especially.

As above-mentioned whitening agent, can enumerate from Placenta Hominis, arbutin, cysteine, ellagic acid, kojic acid, phytic acid, the butyl resorcinol, hydroquinone, Rhizoma Acori Graminei, Semen Armeniacae Amarum, Aloe, Semen Ginkgo, oolong tea, dog rose, Radix Scutellariae, Rhizoma Coptidis, Herba Hyperici Erecti, Herba lamii barbati, Sargassum, Radix Puerariae, Flos Matricariae chamomillae, G1ycyrrhiza glabra, Fructus Gardeniae, Radix Sophorae Flavescentis, Semen Tritici aestivi, rice, Rice plumule, oryzanol, Testa oryzae, Folium Perillae, Radix Paeoniae, Rhizoma Chuanxiong, Cortex Mori, Semen sojae atricolor, tea, thousand fruits, Radix Angelicae Sinensis, Flos Tagetis Erectae, Radix Hamamelidis Mollis, Flos Carthami, Cortex Moutan, Semen Coicis, Radix Angelicae Sinensis, Piao Shu, persimmon (diospyros kaki), the composition of plants such as Flos Caryophylli, extract and quintessence oil etc.In these, preferred arbutin, cysteine, thousand berry extracts.

The mixed proportion of whitening agent used in the present invention is not particularly limited, and can consider that use feeling or physiologically active effect suitably set.For example, the mixed proportion of this whitening agent is generally 0.1～30 weight % with respect to the total amount of topical composition 1, is preferably 0.5～25 weight %, is preferably 1～20 weight % especially.

As above-mentioned anti-wrinkle agent, can enumerate ubiquinone, kinetins, glycolic, six victory peptides, acetylation glycosamine, collagen protein, hyaluronic acid, Aloe extract, Sargassum extract, Aesculus Hippocastanum L. extract, Herba Rosmarini Officinalis extract, Rodgersia podophylla A. Gray extract of Coenzyme Qq6～10 grades etc.Preferred coenzyme Q10 and kinetins.

The mixed proportion of anti-wrinkle agent used in the present invention is not particularly limited, and can consider that use feeling or physiologically active effect suitably set.For example, the mixed proportion of this anti-wrinkle agent is generally 0.1～30 weight % with respect to the total amount of topical composition 1, is preferably 0.5～25 weight %, is preferably 1～20 weight % especially.

As aforementioned analgesic agent, can enumerate indomethacin, felbinac, methyl salicylate, salicylic acid ethanol, allantoin and derivant thereof, ibuprofen, ibuprofen pyrrole methyl ester, bufexamac, butyl flufenamate, bendazac, piroxicam, ketoprofen etc.Be preferably indomethacin, felbinac, methyl salicylate.

The mixed proportion of analgesic agent used in the present invention is not particularly limited, and can consider that use feeling or physiologically active effect suitably set.For example, the mixed proportion of this analgesic agent is generally 0.1～30 weight % with respect to the total amount of topical composition 1, is preferably 0.5～25 weight %, is preferably 1～20 weight % especially.

As above-mentioned antifungal, terbinafine HCl, sulconazole nitrate, clotrimazole, Fazol (Schering), nitric acid croconazole, miconazole nitrate, econazole nitrate, oxiconazole, bifonazole, tioconazole, ketoconazole,, tolnaftate, tolciclate, liranaftate, ciclopirox olamine, exalamide, siccanin, 9-undecylenic acid, Zinc Undecenoate, pyrrolnitrin, butenafine hydrochloride, hydrochloric acid amorolfine, SS 717 etc.Preferred terbinafine HCl, sulconazole nitrate.

The mixed proportion of antifungal used in the present invention is not particularly limited, and can consider that use feeling or physiologically active effect suitably set.For example, the mixed proportion of this antifungal is generally 0.1～30 weight % with respect to the total amount of topical composition 1, is preferably 0.5～25 weight %, is preferably 1～20 weight % especially.

As the aforementioned steroid agent, the dexamethasone valerate acetate, dexamethasone, the propanoic acid dexamethasone, dexamethasone acetate, the valeric acid dexamethasone, prednisolone valerate acetate, hydrocortisone butyrate, hydrocortisone acetate, hydrocortisone, pandel, cortisone acetate, prednisolone acetate, prednisolone, betamethasone, celestone-V, the betamethasone dipropionate, clobetasone butyrate, the propanoic acid clobetasone, acetic acid diflorasone, the valeric acid diflorasone, beclometasone, the flumetasone pivalate, acetone fluorine hydroxyl sprinkles mud pine dragon, fluocinonide, fluocinolone acetonide, amcinonide, halcinonidedcorten, difluprednate etc.Preferred hydrocortisone butyrate, prednisolone valerate acetate, clobetasone butyrate.

The mixed proportion of steroid dose used in the present invention is not particularly limited, and can consider that use feeling or physiologically active effect suitably set.For example, the mixed proportion of this steroid agent is generally 0.1～30 weight % with respect to the total amount of topical composition 1, is preferably 0.5～25 weight %, is preferably 1～20 weight % especially.

Educate a mao agent as above-mentioned, proanthocyanidin is arranged, glycyrrhizic acid dipotassium, Ytterbium trichloride, cepharanthine, menthol, the Chinese juniper another name for, the L-hydroxyproline, the acetyl hydroxyproline, fucoidan, the Fructus Capsici tincture, cepharanthine, when the medicine Oxoxanthone, シ Application ホ Application グギニジ Application, the flavonoid sterin, the immunity thiabendazole, minoxidil, FGF-10, prolong the careless extract of life, Herba Swertiae bimaculatae extract, three stone Thallus Laminariae (Thallus Eckloniae) extracts, Herb Gynostemmae Pentaphylli extract, the Herba Hyperici Erecti extract, Radix Gentianae extract, sage extract, the Oleum menthae extract, the hops extract, Semen Coicis extract, Folium Kaki extract, Radix Rehmanniae extract, Radix Ginseng extract, the bodhi tree extract, Cortex Moutan extract etc.Preferred proanthocyanidin, Herba Swertiae bimaculatae extract, three stone Thallus Laminariae (Thallus Eckloniae) extracts.

Mixed proportion of educating mao agent used in the present invention is not particularly limited, and can consider that use feeling or physiologically active effect suitably set.For example, this educates the total amount of the mixed proportion of mao agent with respect to topical composition 1, is generally 0.1～30 weight %, is preferably 0.5～25 weight %, is preferably 1～20 weight % especially.

As above-mentioned weight reducing agent, can enumerate xanthines such as caffeine, aminophylline, theophylline, Oxtriphylline, glycerol dish alkali, two isobutyl aminobenzoic acyl-oxygen propyl group theophylline, theobromine, diprophylline, proxyphylline, pentoxifylline; Capsaicin etc.Preferably coffee alkali, capsaicin.

The mixed proportion of weight reducing agent used in the present invention is not particularly limited, and can consider that use feeling or physiologically active effect suitably set.For example, the mixed proportion of this weight reducing agent is generally 0.1～30 weight % with respect to the total amount of topical composition 1, is preferably 0.5～25 weight %, is preferably 1～20 weight % especially.

Above-mentioned local anesthetic, pruritus, antibacterial, antiviral agent, keratolytic, wetting agent, astringent, antioxidant and hair inhibitor can be listed below.

Local anesthetic: lignocaine, lidocaine hydrochloride, cinchocaine, hydrochloric acid cinchocaine, benzocaine, eucalyptus oil, eugenol, Camphora, Herba Menthae wet goods.

Pruritus: crotamiton, chlorphenamine, chlorphenamine maleate, diphenhydramine, diphhydramine hydrochloride, diphenhydramine salicylate, salicylic acid, 4-hydroxyl-3-methoxyl group n-nonanoic acid ammonium, mequitazine, Camphora, thymol, eugenol, polyoxyethylene laurel ether, Radix Arnebiae extract, Folium perillae extract etc.

Antibacterial: Isopropylmethylphenol, chlorhexidine gluconate, Chlorhexidine hydrochloride, benzalkonium chloride, benzethonium chloride, cetyl trimethyl ammonium bromide, dequalinium chloride, triclosan, trichloro-symmetrical diphenyl urea etc.

Antiviral agent: aciclovir, penciclovir etc.

Keratolytic: ethanol, isopropyl alcohol, propanol, butanols Polyethylene Glycol, benzyl alcohol, phenethanol, third rare carbonic ester, hexyl dodecanol, allantoin, dimethyl sulfoxide, dimethyl acetylamide, dimethyl formamide, triethanolamine, diisopropyl adipate ester, ethyl laurate, lanoline, fatty acid dihydroxy amine, carbamide, sulfur, resorcinol, phytic acid, lactic acid, lactate, sodium hydroxide, calcium hydroxide etc.

Wetting agent: macromolecular compounds such as hyaluronic acid, derivatives of hyaluronic acids (for example hyaluronan), hyaluronate, Polyethylene Glycol, two glyceryl trehaloses, heparin class, sodium chondroitin sulfate, collagen protein, elastin laminin, keratin, chitin, chitosan; Nature moisturizing factor such as aminoacetic acid, aspartoyl amino acid, arginine, sodium lactate, carbamide, pyrrolidone sodium carboxylate; Plant extraction extracts such as camomile extract, Aloe extract, aloe vera extract, Radix Hamamelidis Mollis extract, Herba Rosmarini Officinalis extract, Thymi Serpylli Herba extract, tea extract, Folium perillae extract.

Astringent: citric acid, tartaric acid, lactic acid, aluminum chloride, aluminum sulfate, ALCA, allantoin dihydroxy aluminum, aluminium phenolsulfonate, p-phenolsulfonic acid's zinc, zinc sulfate, zinc lactate, chlorine hydroxy Al etc.

Antioxidant: dibenzylatiooluene, hydroxyl Fructus Foeniculi dibutyl ester, disodiumedetate two hydrates (the following edetate sodium that also claims), sorbic acid, sodium sulfite etc.

Hair inhibitor: isoflavone, Rhizoma Belamcandae extract, Herba Houttuyniae extract, iris germanica extract, papain etc.

Local anesthetic, pruritus, antibacterial, antiviral agent, keratolytic, wetting agent, astringent, antioxidant and the mixed proportion of hair inhibitor in external compositions 1 are, not hinder effect of the present invention is boundary, though not restriction especially, but preferably pharmacy or that fragrant woman's persona is learned permission upper limit ratio is the boundary, can suitably set.Specifically, relative topical composition 1 total amount, the mixed proportion of each physiologically active ingredient is 0.001～20 weight % normally, preferred 0.001～10 weight %, more preferably 0.001～5 weight %.

(2) embodiment 2

The second, the present invention reaches (ii) list or low diol ether by containing (i) phospholipid with special ratios respectively, and the topical composition of the percutaneous absorbability increase of contained physiologically active ingredient is provided.

That is, topical composition of the present invention (below be labeled as topical composition 2) is characterized in that, topical composition total amount relatively contains (i) phospholipid 0.01～8 weight %, and (ii) list or low diol ether 0.01～6.5 weight %.

The mixed proportion of (i) phospholipid is 0.01～8 weight % of these topical composition 2 total amounts in the topical composition 2 of the present invention.(i) mixed proportion of phospholipid, preferred 0.1～7.5 weight %, more preferably 1～7 weight %.

And the (ii) list in the topical composition 2 of the present invention or the mixed proportion of low diol ether are 0.01～6.5 weight % of these topical composition 2 total amounts.The (ii) mixed proportion of list or low diol ether, preferred 0.1～6 weight %, more preferably 1～5 weight %.

As mentioned above, set (i) phospholipid and the (ii) mixed proportion of list or low diol ether respectively, make it reach above-mentioned scope, can further improve the percutaneous absorbability of physiologically active ingredient.

In topical composition 2 of the present invention, the relatively (ii) list of (i) phospholipid or the mixed proportion of low diol ether are satisfying above-mentioned (i) phospholipid and are (ii) suitably setting in the scope of the mixed proportion separately of list or low diol ether.Specifically, relative (i) phospholipid 1 weight portion, (ii) list or low diol ether are generally 0.01～70 weight portion, preferred 0.05～50 weight portion, more preferably 0.1～20 weight portion.

In topical composition 2 of the present invention,, also contain (iii) physiologically active ingredient except above-mentioned (i) phospholipid and (ii) list or the low diol ether.Add the kind and the mixed proportion thereof of the (iii) physiologically active ingredient in the topical composition 2 of the present invention, identical with the situation of above-mentioned topical composition 1.

(3) embodiment 3

The 3rd, the invention provides topical composition, said composition has improved the percutaneous absorbability of hyaluronic acid, derivatives of hyaluronic acids, vitamin A, vitamin A derivative, vitamin C, specific vitamin C derivatives, xanthine derivative, ubiquinone and/or these salt.The raising of the percutaneous absorbability of these specific physiologically active ingredients can be by with above-mentioned (i) phospholipid and (ii) list or low diol ether are mixed into topical composition and reach.

Promptly, topical composition of the present invention (below be labeled as topical composition 3) contains (i) phospholipid, (ii) list or low diol ether and (iv) be selected from least a physiologically active ingredient in hyaluronic acid, derivatives of hyaluronic acids, vitamin A, vitamin A derivative, vitamin C, specific vitamin C derivatives, xanthine derivative, ubiquinone and/or these the salt.

The mixed proportion of (i) phospholipid in the topical composition 3 of the present invention has no particular limits, and with respect to the total amount of this topical composition 3, is generally 0.01～15 weight %, preferred 0.05～10 weight %, preferred especially 0.1～8 weight %.

And in topical composition 3 of the present invention, (ii) the mixed proportion of list or low diol ether also has no particular limits, and can consider the usability of skin and the percutaneous absorbability of physiologically active ingredient etc. are suitably set.As an example, be 0.01～80 weight % with respect to these topical composition 3 total amounts, preferred 1～75 weight %, preferred especially 5～70 weight %.

In topical composition 3 of the present invention, the relatively (ii) list of (i) phospholipid or the mixed proportion of low diol ether are satisfying above-mentioned (i) phospholipid and are (ii) suitably setting in the scope of the mixed proportion separately of list or low diol ether.Specifically, relative (i) phospholipid 1 weight portion, (ii) list or low diol ether are generally 0.01～300 weight portion, preferred 0.05～100 weight portion, more preferably 0.1～20 weight portion.

In topical composition 3 of the present invention, as (iv) physiologically active ingredient, contain and be selected from (iv-1) hyaluronic acid, derivatives of hyaluronic acids and/or its salt, (iv-2) vitamin A and/or vitamin A derivative, (iv-3) vitamin C, its salt and/or specific vitamin C derivatives, (iv-4) xanthine derivative, and (iv-5) a kind of or two or more in the ubiquinone.

The mixed proportion of the (iv) physiologically active ingredient in the topical composition 3 of the present invention, suitably set according to the kind of physiologically active ingredient, the form of this topical composition 3 etc., the total amount of usually relative topical composition 3, (iv) the total amount of physiologically active ingredient is 0.0001～50 weight %, preferred 0.0005～40 weight % is more preferably the ratio of 0.001～30 weight %.

The source of (iv-1) hyaluronic acid, derivatives of hyaluronic acids and/or its salt that uses among the present invention (below, simple marking is " (iv-1) composition " sometimes) has no particular limits, and for example, can be from cockscomb, also can be from microorganism.

As an example of derivatives of hyaluronic acids, can exemplify hydrogen atom on the hyaluronic hydroxyl by the metathetical ester derivant of acyl group.This ester derivant for example, in each hyaluronic formation unit (2 sugar), has 2～4 acyl groups.As this acyl group, specifically, can exemplify alkanoyl, aromatic carbonyl.As alkanoyl, the material of preferred carbon number 1～12 specifically, can exemplify acetyl group, propiono, bytyry etc.In addition, as aromatic carbonyl, preferred carbon number is 7～1 5 material, specifically, can exemplify benzoyl, naphthalene carboxyl etc.In addition, this alkanoyl and aromatic carbonyl can be that 1～6 alkyl, carbon number are displacements such as 1～6 alkoxyl, halogen atom, amino, hydroxyl by carbon number also.When this alkanoyl and aromatic carbonyl were replaced, its substituent quantity had no particular limits, and is generally 1～3.

And then, as other examples of hyaluronic derivant, can exemplify hyaluronic hydroxyl alkoxy, aryloxy group and/or the metathetical ether derivant of alkenyloxy.This ether derivant for example, in each hyaluronic formation unit (2 sugar), has 1～3 alkoxyl, aryloxy group and/or alkenyloxy.As this alkoxyl, preferred carbon number is 1～6 material, specifically, can exemplify methoxyl group, ethyoxyl, positive propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentyloxy, neopentyl oxygen, positive hexyloxy etc.In addition, as this aryloxy group, specifically, can exemplified by phenyl, naphthyl etc.And then as this alkenyloxy, preferred carbon number is 2～6 material, can exemplify ethyleneoxy, third rare oxygen base etc.In addition, this alkoxyl, aryloxy group and/or alkenyloxy can be that 1～6 alkyl, carbon number are displacements such as 1～6 alkoxyl, halogen atom, amino, hydroxyl by carbon number also.When alkoxyl, aryloxy group and/or alkenyloxy were replaced, its substituent quantity had no particular limits, and was generally 1～3.

These hyaluronic derivants can be used alone, and also can be used in combination two or more.As the suitable example of derivatives of hyaluronic acids, can exemplify hydrogen atom on the hyaluronic hydroxyl by the metathetical hyaluronan of acetyl group.Hyaluronic acid has the substituent number of acetyl group and is preferably 2～4 in each hyaluronic formation unit (2 sugar).

As the salt of hyaluronic acid and derivant thereof, can be widely used in the salt that is allowed on its pharmacy physiology.As such salt, can exemplify the alkali metal salt of sodium or potassium etc.; The alkali salt of magnesium or calcium etc.; Ammonia salt, the alkanolamine of monoethanolamine etc. etc.

In addition, the mean molecule quantity of hyaluronic acid and/or its salt has no particular limits, and is generally 1,000～5,000,000, and is preferred 2,000～4,000,000, is more preferably 3,000～2,500,000.Hyaluronic molecular weight is so big, and percutaneous when using is difficult to Transdermal absorption and can be stuck on the epidermis so as everyone knows it is mixed into topical composition in the past.Therefore, in topical composition in the past,, also fail to obtain desired physiologically active even hyaluronic acid transdermal is used.With respect to this, according to topical composition 3 of the present invention, can improve so hyaluronic shortcoming, the hyaluronic acid that percutaneous uses can be given full play to original physiologically active.

As above-mentioned (iv-1) composition, the alkali metal salt of preferably clear matter acid is more preferably hyaluronate sodium.

In topical composition 3 of the present invention, when mixing (iv-1) composition as (iv) physiologically active ingredient, its mixed proportion can suitably be set in the scope of the mixed proportion of above-mentioned (iv) physiologically active ingredient.Example as the mixed proportion of more suitable (iv-1) composition can exemplify, and is 0.0001～10 weight % with respect to the total amount of topical composition 3, and preferred 0.0005～8 weight % is more preferably 0.001～5 weight %.

In addition, as (iv-2) vitamin A that uses in the present invention and/or vitamin A derivative (below, sometimes simple marking is " (iv-2) composition "), specifically, can exemplify retinol, retinal, acetic acid retinal, tretinoin, tretinoin methyl ester, tretinoin ethyl ester, tretinoin retinol ester, vitamin A fatty acid ester, d-δ-Wei A fertility alcohol ester, α-Wei A fertility alcohol ester and β-Wei A fertility alcohol ester etc.At this, vitamin A fatty acid ester be vitamin A and carbon number be 12～18 fatty acid by the bonded chemical compound of ester, specifically, can exemplify tetradecanoic acid retinol ester, stearic acid retinol ester, hexadecanoic acid retinol ester etc.These (iv-2) compositions can be used alone, and also can be used in combination two or more.And then, as (iv-2) composition, also can use vitamin A oil.As (iv-2) composition, preferred d-δ-Wei A gives birth to alcohol ester.

In topical composition 3 of the present invention, when mixing (iv-2) composition as (iv) physiologically active ingredient, its mixed proportion, can be in the scope of the mixed proportion of above-mentioned (iv) physiologically active ingredient, according to the form of this topical composition 3, the usability of skin, desired physiological action etc. are suitably set, mixed proportion as (iv-2) composition that is fit to more, can exemplify, the total amount of topical composition 3 is 0.01～5 weight % relatively, preferred 0.1～3 weight % is more preferably 0.2～1 weight %.

In the present invention (iv-3) vitamin C of Shi Yonging, its salt and/or specific vitamin C derivatives (below, sometimes simple marking is " (iv-3) composition "), specifically, can exemplify salt, hydroascorbic acid, ascorbate glucoside, ascorbyl stearate, L-Vitamin C dipalmitate and/or the VC-IP of ascorbic acid, ascorbic acid.As the salt of ascorbic acid, for example can exemplify the alkali metal salt of ascorbic acid, more particularly, sodium ascorbate.These (iv-3) compositions can be used alone, and also can be used in combination two or more.And then, as (iv-3) composition, preferred ascorbic acid, ascorbate glucoside, VC-IP.

In topical composition 3 of the present invention, when mixing (iv-3) composition as (iv) physiologically active ingredient, its mixed proportion, can be in the scope of the mixed proportion of above-mentioned (iv) physiologically active ingredient, according to the form of this topical composition 3, the usability of skin, desired physiological action etc. are suitably set.Mixed proportion as (iv-3) composition that is fit to more can exemplify, and the total amount of topical composition 3 is 0.01～50 weight % relatively, and preferred 0.05～40 weight % is more preferably 0.1～30 weight %.

In the present invention (iv-4) xanthine derivative of Shi Yonging (below, sometimes simple marking is " (iv-4) composition "), specifically, can exemplify caffeine, aminophylline, theophylline, Oxtriphylline, glycerol dish alkali, two isobutyl aminobenzoic acyl-oxygen propyl group theophylline, theobromine, diprophylline, proxyphylline and pentoxifylline.These (iv-4) compositions can be used alone, and also can be used in combination two or more.And then, as (iv-3) composition, preferably coffee alkali, aminophylline, theophylline, diprophylline, proxyphylline and theobromine.Special preferably coffee alkali.

In topical composition 3 of the present invention, when mixing (iv-4) composition as (iv) physiologically active ingredient, its mixed proportion, can be in the scope of the mixed proportion of above-mentioned (iv) physiologically active ingredient, according to the form of this topical composition 3, the usability of skin, desired physiological action etc. are suitably set.Mixed proportion as (iv-4) composition that is fit to more can exemplify, and the total amount of topical composition 3 is 0.01～50 weight % relatively, and preferred 0.1～3 weight % is more preferably 0.2～1 weight %.

(iv-5) ubiquinone of Shi Yonging (below, simple marking is " (iv-5) composition " sometimes) is 2 in the present invention, 3-dimethoxy-5-methyl-6-polyprene base-1, and the general name of 4-benzoquinone is also referred to as ubiquinone.Ubiquinone, the isoprene unit of side chain is preferred 1～20, and is preferred 5～15, be more preferably 6～10 (Coenzyme Qq6～Q10), preferred especially 10 (coenzyme Q10s).These (iv-5) compositions can be used alone, and also can be used in combination two or more.

In topical composition 3 of the present invention, when mixing (iv-5) composition as (iv) physiologically active ingredient, its mixed proportion, can be in the scope of the mixed proportion of above-mentioned (iv) physiologically active ingredient, according to the form of this topical composition 3, the usability of skin, desired physiological action etc. are suitably set.Mixed proportion as (iv-5) composition that is fit to more can exemplify, and the total amount of topical composition 3 is 0.001～5 weight % relatively, and preferred 0.05～3 weight % is more preferably 0.1～1 weight %.

Topical composition 3 of the present invention, other compositions for beyond above-mentioned (iv-1)～(iv-5) composition also can promote Transdermal absorption, therefore, further mix other physiologically active ingredients as required, can add useful physiologically active.

As can blended physiologically active ingredient beyond above-mentioned (iv-1)～(iv-5) composition,, then its kind be had no particular limits as long as can produce beneficial effect for skin.Specifically, as can blended other physiologically active ingredients in topical composition 3 of the present invention, can exemplify as among the composition that blended (iii) physiologically active ingredient exemplifies in above-mentioned topical composition 1 material except above-mentioned (iv-1)～(iv-5) composition.In addition, the mixed proportion of these other physiologically active ingredients is identical with the situation of above-mentioned topical composition 1.

In this manual, in the explanation of following " 4. other blending constituents ", " the 5. dosage form of topical composition " and " 6. purposes " part, said topical composition comprises the whole of above-mentioned topical composition 1～3 in its implication.

4. other blending constituents

Topical composition of the present invention as required, can further contain water.When water was mixed into topical composition of the present invention, its mixed proportion had no particular limits, and with respect to the total amount of topical composition, usually water is 0.001～75 weight %, and preferred 0.01～70 weight % is more preferably the ratio of 0.1～65 weight %.

And then topical composition of the present invention also can contain polyhydric alcohol.By containing polyhydric alcohol, can further promote the Transdermal absorption of physiologically active ingredient, reach beneficial effect.As polyhydric alcohol, so long as in the external compositions normally used material, then have no particular limits, can exemplify glycerol, ethylene glycol, propylene glycol, dipropylene glycol, 1,2-butanediol, 1,3 butylene glycol, 2,3-butanediol, isobutyl glycol, 1,2-pentanediol, 1,2-hexanediol, ethohexadiol and these condensation polymer.As above-mentioned condensation polymer, can exemplify two glycerol, diethylene glycol, triethylene glycol, TEG, dipropylene glycol, tripropylene glycol etc.During polyols blend, its mixed proportion has no particular limits in topical composition of the present invention, and with respect to the total amount of topical composition, polyhydric alcohol is 1～40 weight % usually, and preferred 5～35 weight are more preferably the ratio of 10～30 weight %.

Topical composition of the present invention, outside above-mentioned blending constituent, do not influencing qualities such as storage stability and viscosity, and do not influence in the scope of effect of the present invention, as required, can cast aside and compositions such as normally used various bases, carrier, other additives in pharmaceuticals, similar pharmaceuticals or cosmetic field.As such composition, can exemplify base, surfactant, viscosifier, preservative agent, pH adjustment agent, stabilizing agent, stimulation palliative, antiseptic, coloring agent, dispersant, spice etc.These compositions can be used alone, and also can combination in any use two or more.Below, for these compositions, enumerate object lesson, but be not limited to these.

Base: Hydrocarbon such as paraffin, gel Hydrocarbon, ceresine, ceresin, vaseline, tristearin, microwax; Fatty acids such as dodecylic acid, tetradecanoic acid, hexadecanoic acid, stearic acid, behenic acid, isostearic acid, oleic acid, linoleic acid; Triglycerides such as three 2 ethyl hexanoic acid glyceride; High polymerization methyl polysiloxane, dimethyl siloxane/methyl (polyoxyethylene) siloxanes/methyl (polyoxypropylene) silicone copolymers, dimethyl siloxane/methyl (polyoxyethylene) silicone copolymers, dimethyl siloxane/methyl (polyoxypropylene) silicone copolymers, polyoxyethylene/methyl polysiloxane copolymer, poly-(oxygen ethylene/oxypropylene)/methyl polysiloxane copolymer, the stearic oxygen radical siloxane of dimethyl siloxane/methyl copolymer, alkyl acrylate copolymer methyl polysiloxane ester, the cross-linking type methyl polysiloxane, the cross-linking type methyl phenyl silicone, the polyether-modified silicon of cross-linking type, cross-linking type alkyl, polyether modification silicon, aggretion type silicon such as the alkyl-modified silicon of cross-linking type; Ethylene glycol acetate, ethylene acetate, triethylene glycol diacetate esters, hexanediol diacetate esters and 2-methyl-2-third are rare-1, ethyl glycol acetates such as 1-glycol diacetate; Triethylene glycol two valerates, 2,2,4-trimethyl-1,3-pentane diol mono isobutyrate, 2,2,4-trimethyl-1, diol esters such as 3-pentane diol diisobutyrate; Acrylic acid glycol ester, ethylene glycol bisthioglycolate diester acrylates, propylene glycol mono acrylic ester, 2, glycol acrylate such as 2-dimethyl propylene omega-diol diacrylate and 1,3 butylene glycol diacrylate; Glycol dinitrates such as dinitroglycol, diethylent glycol dinitrate, dipropylene glycol dinitrate and propylene glycol dinitrate; 2,2 '-[1,4-benzene dioxy base] diethanol; Diox; Butanediol adipate polyester etc.

Surfactant: sorbitan fatty acid ester classes such as sorbitan list isostearate, Span-20, sorbitan monopalmitate, sorbitan monostearate, five-2 ethyl hexanoic acid, two glycerol sorbitan esters, four-2 ethyl hexanoic acid, two glycerol sorbitan esters; Glycerine fatty acid esters such as glyceryl monostearate, glycerol monostearate malate; Methyl glycol fatty acid ester classes such as poly-glycerine fatty acid ester, propylene glycolmonostearate such as single isostearic acid polyglycerol esters, two isostearic acid polyglycerol esters, polyoxyethylene solidify Oleum Ricini 40, polyoxyethylene solidifies Oleum Ricini 60, polyoxyethylene curing Oleum Ricini 80 etc. and solidifies castor oil derivative; Mono laurate polyoxyethylene (20) sorbitan (polysorbate 20), monostearate polyoxyethylene (20) sorbitan (polysorbate 60), mono laurate polyoxyethylene (20) sorbitan polyoxyethylene sorbitan fatty acid esters such as (polysorbate 80s) class, polyoxyethylene list Castor Oil Fatty Acid glyceride, alkyl glycerylether, alkyl-glucoside, Polyoxyethylene cetyl ether, Stearyl Amine, oleyl amine etc.

Viscosifier: guar gum, locust bean gum, carrageenin, Xanthan gum, dextran, methylcellulose, ethyl cellulose, carboxymethyl cellulose, hydroxyethyl-cellulose, the hydroxyalkyl vinyl cellulose, hydroxypropyl cellulose, hydroxypropyl emthylcellulose, Sodium Alginate, the alginic acid propylene glycol ester, polyvinyl alcohol, polyvinylpyrrolidone, polyvinyl methyl ethermaleic anhydride, CVP Carbopol ETD2050, acrylic acid alkyl methacrylate copolymer, sodium polyacrylate, Polyethylene Glycol, bentonite, dextrin fatty acid ester, pectin etc.

Preservative agent: benzoic acid, sodium benzoate, dehydroactic acid, p-Hydroxybenzoic acid isobutyl ester, p-Hydroxybenzoic acid isopropyl ester, butyl p-hydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate, P-hydroxybenzoic acid phenyl ester, methyl parahydroxybenzoate, phenyl phenol etc.

PH adjusts agent: mineral acids such as hydrochloric acid, sulphuric acid, phosphoric acid, polyphosphoric acid, boric acid; Organic acid such as lactic acid, acetic acid, citric acid, tartaric acid, malic acid, succinic acid, sodium succinate, oxalic acid, gluconic acid, fumaric acid, propanoic acid, acetylenecarboxylic acid, acetic acid, agedoite acid, episilon amino caproic acid, glutamic acid, amino-ethyl sulfonic acid; Gluconolactone; Ammonium acetate; Inorganic bases such as sodium bicarbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, calcium hydroxide, magnesium hydroxide; Organic bases such as monoethanolamine, triethanolamine, diethyl Propanolamine, three b propanol amine, lysine etc.

The blending constituent of these compositions only otherwise influence effect of the present invention, then has no particular limits.Specifically, the mixed proportion of above-mentioned these each compositions with respect to the total amount of topical composition, is generally 0.001～20 weight %, and preferred 0.001～10 weight % is more preferably 0.001～5 weight %.

5. the dosage form of topical composition

Topical composition of the present invention can be any form in aqueous, semi-solid, the solid shape.Therefore, topical composition of the present invention can be prepared into various dosage forms according to its purposes.The dosage form that topical composition of the present invention can adopt can exemplify ointment, cream, liquor, gel agent, solid agent, patch etc.At this, comprise oily, lotion shape, emulsion form, gas glue, liquid crystal shape, microemulsion shape and liposome shape in the liquor.In addition, comprise liquid crystal shape, microemulsion shape, liposome shape in cream and the gel agent.Comprise microemulsion shape, liposome shape in the patch.And then, Gu comprise lever-like in the agent.In these dosage forms, preferred liquor, gel agent.Especially, as embodiments of the present invention, preferred especially gel agent.The below implication of explanation " liquid crystal ", " microemulsion " and " liposome ", concrete form etc.

Liquid crystal generally is meant to possess the highly crystalline that has long orientation in constituting molecule, has the flowability between solid and the liquid and the liquid of toughness simultaneously, demonstrates optical anisotropy usually.Liquid crystal is formed with hexagonal crystal layer and lamella, owing to this structure, the candy strip of color occurs having in white light, or because of polarisation two produces refraction, reflection, therefore, by the birefringence or the visual formation that can distinguish liquid crystal easily of microscopically.Therefore the similar of liquid crystal and organism two-fold film and iuntercellular lipid infiltrates skin easily, and has the advantage of the Transdermal absorption that can promote useful component.Because above-mentioned reason as the preferred form of topical composition of the present invention, exemplifies the liquid crystal type topical composition that is dispersed with liquid crystal.The manufacture method of liquid crystal type topical composition is known.For example, this liquid crystal type topical composition, by add mixed phosphatide matter, water soluble compound, low amounts of water in list or low diol ether, then suitably interpolation mixes oil content and oil-soluble compounds etc. and prepares.In addition, this liquid crystal type topical composition though can mix low amounts of water, can additionally not add water yet and is prepared into water-free in fact preparation.

In addition, microemulsion because micelle that is scattered here and there is little, is therefore compared with common emulsion, easier from horny layer by skin absorbs.Because above-mentioned reason as the preferred form of topical composition of the present invention, exemplifies the micro-emulsion type topical composition with microemulsion.At this, the mean diameter of microemulsion, in order to ensure optical transparence, preferred little below 0.5 micron.The manufacture method of micro-emulsion type topical composition is known.For example, this micro-emulsion type topical composition by add mixed phosphatide matter etc. in list or low diol ether, then suitably adds and mixes oil content and oil-soluble compounds etc., further suitably make a brief trip home afterwards water soluble compound and water, and use the high-pressure emulsification homogenizer to carry out emulsifying and prepare.

In addition, liposome is the endoplasmic reticulum that is made of glomerate lipid bilayer.Therefore the similar of liposome and organism two-fold film infiltrates skin easily, and has the advantage of the Transdermal absorption that can promote useful component.Because above-mentioned reason as the preferred form of topical composition of the present invention, exemplifies the lipid build topical composition that contains liposome.At this, this liposome can be a monolayer, also can be multilamellar.The manufacture method of lipid build topical composition is known.For example, this lipid build topical composition, by suitable mixed phosphatide matter, water soluble compound, the water etc. of adding in list or low diol ether, and then suitably interpolation mixes oil content and oil-soluble compounds etc. and prepares.

6. purposes

Topical composition of the present invention can belong to any category in pharmaceuticals (comprising similar pharmaceuticals), the cosmetic raw material, can be used for various uses according to the kind of contained physiologically active ingredient.

Topical composition of the present invention is to the use amount and the usage of skin, can suitably set according to form of the kind of employed physiologically active ingredient and mixed proportion, this topical composition etc.

Topical composition of the present invention according to form of topical composition etc., can mix each composition according to conventional methods and prepares.

B. the improvement method of percutaneous absorbability

The present invention is as described in above-mentioned " (1) embodiment 1 of the 3rd of A. topical composition " part, by in containing the topical composition of (iii) physiologically active ingredient, mix (i) phospholipid, further mix 22 weight % above (ii) list or low diol ether, can further improve the (iii) percutaneous absorbability of physiologically active ingredient.Promptly, the invention provides the (iii) improvement method of the percutaneous absorbability of physiologically active ingredient, it is characterized in that, in containing the topical composition of (iii) physiologically active ingredient, contain (i) phospholipid 0.01～8 weight %, and, contain (ii) list or low diol ether 0.01～6.5 weight % with respect to the total amount of topical composition.

In addition, the present invention is as described in above-mentioned " (2) embodiment 2 of the 3rd of A. topical composition " part, by in containing the topical composition of (iii) physiologically active ingredient, mix (i) phospholipid 0.01～8 weight %, and (ii) list or low diol ether 0.01～6.5 weight %, can improve the (iii) percutaneous absorbability of physiologically active ingredient.Promptly, the invention provides the (iii) improvement method of the percutaneous absorbability of physiologically active ingredient, it is characterized in that, in containing the topical composition of (iii) physiologically active ingredient, contain (i) phospholipid 0.01～8 weight %, and, contain (ii) list or low diol ether 0.01～6.5 weight % with respect to the total amount of topical composition.

And then, the present invention is as described in above-mentioned " (3) embodiment 3 of the 3rd of A. topical composition " part, by in containing the topical composition of (iv) specific physiologically active ingredient, mix (i) phospholipid and (ii) list or low diol ether, can improve the (iv) percutaneous absorbability of specific physiologically active ingredient.Promptly, the invention provides the (iv) improvement method of the percutaneous absorbability of physiologically active ingredient, it is characterized in that, in containing the topical composition that (iv) is selected from least a physiologically active ingredient in hyaluronic acid, vitamin A, vitamin A derivative, vitamin C, specific vitamin C derivatives, xanthine derivative, ubiquinone and their salt, contain (i) phospholipid and (ii) list or low diol ether.

Embodiment

Below, describe the present invention in detail by embodiment.But the present invention is not limited to these embodiment.Need to prove that the combined amount in following embodiment all is meant weight % when not putting down in writing unit especially.

Test routine 1-1

According to the prescription shown in the table 1, the preparation topical composition.Specifically, with the dissolving of heating of phospholipid, low diol ether and the polyhydric alcohol of ormal weight, in the lysate that obtains, mix the aqueous ascorbic acid of heating in addition.And then, in the mixed liquor that obtains, further add the neccessary composition of ormal weight, prepared the topical composition (beyond the comparative example 1-3 is the lipid build) of embodiment 1-1～1-2 and comparative example 1-1～1-3.For each topical composition, vessel side at the Franz of longitudinal type diffusion cell adds phosphate buffer (pH7.4) 10ml, the holostrome skin of the removal fat of nude mouse (system: HR-1,7 week ages, male) is fixed between the diffusion cell, adds above-mentioned topical composition 1ml in the donor side afterwards.Add after 30 hours, carried out quantitatively for the ascorbic acid concentrations in the phosphate buffer of vessel side by HPLC.

The result is as shown in table 1.In table 1, transit dose (μ g/cm ²) be illustrated in after topical composition added 30 hours, see through the every 1cm of holostrome skin of nude mouse ²The amount (μ g) of ascorbic acid.

Table 1

g/100g	Embodiment 1-1	Embodiment 1-2	Comparative example 1-1	Comparative example 1-2	Comparative example 1-3
g/100g	Embodiment 1-1	Embodiment 1-2	Comparative example 1-1	Comparative example 1-2	Comparative example 1-3	Hydrogenated soya phosphatide matter ^*1	5	-	5	5	-
Soybean phospholipid matter ^*2	-	1	5	5	-	Hydrogenated soya phosphatide matter ^*1	5	-	5	5	-
Soybean phospholipid matter ^*2	-	1	5	5	-	Ascorbic acid	10	20	10	10	20
Ethoxydiglycol	43	49	-	-	53	Ascorbic acid	10	20	10	10	20
Ethoxydiglycol	43	49	-	-	53	Glycerol	-	-	43	-	-
1,3 butylene glycol	-	-	-	43	-	Glycerol	-	-	43	-	-
1,3 butylene glycol	-	-	-	43	-	Oleyl amine	1	1	-	-	-
Two glycerol	-	-	-	-	4	Oleyl amine	1	1	-	-	-
Two glycerol	-	-	-	-	4	Trimethyl glycine	-	-	-	-	3
Water purification	Surplus	Surplus	Surplus	Surplus	Surplus	Trimethyl glycine	-	-	-	-	3
Water purification	Surplus	Surplus	Surplus	Surplus	Surplus	Transit dose (30 hours) (μ g/cm ²)	1118	6350	359	397	174

^*1 SLP-PC92H (iodine number is below 45); Tsuji System oil society makes

^*2 SLP-PC70; Tsuji System oil society makes

In the topical composition of embodiment 1-1,, demonstrated the transit dose of the ascorbic acid more than 2.8 times with respect to the topical composition of comparative example 1-1 and 1-2.In addition, the topical composition of embodiment 1-1 with respect to the topical composition of comparative example 1-3, has demonstrated the transit dose of the ascorbic acid more than 6.4 times.And then, having mixed the topical composition that does not have the embodiment of hydrogenant soybean phospholipid matter 1-2, the transit dose of its ascorbic acid is more than 16 times with respect to the topical composition of comparative example 1-1 and 1-2, is more than 36 times with respect to the topical composition of comparative example 1-3.

Test routine 1-2

According to the prescription shown in the table 2, the preparation topical composition.Specifically,, in the lysate that obtains, mix the ascorbic acid of heating in addition and the aqueous solution of oleyl amine, prepared the topical composition of embodiment 1-3～1-5 the dissolving of heating of phospholipid, low diol ether and the polyhydric alcohol of ormal weight.

The topical composition of embodiment 1-3～1-5 has all demonstrated the percutaneous absorbability of good ascorbic acid.

Table 2

g/100g	Embodiment 1-3	Embodiment 1-4	Embodiment 1-5
g/100g	Embodiment 1-3	Embodiment 1-4	Embodiment 1-5	Hydrogenated soya phosphatide matter ^*	5	1	10
Ascorbic acid	10	10	5	Hydrogenated soya phosphatide matter ^*	5	1	10
Ascorbic acid	10	10	5	Ethoxydiglycol	43	43	25
Oleyl amine	1	0.5	1	Ethoxydiglycol	43	43	25
Oleyl amine	1	0.5	1	1,3 butylene glycol	-	-	18
Water purification	Surplus	Surplus	Surplus	1,3 butylene glycol	-	-	18

^*SLP-PC92H (iodine number is below 45); Tsuji System oil society makes

Test routine 1-3

According to the prescription shown in the table 3, the preparation topical composition.Specifically, with the dissolving of heating of phospholipid, each physiologically active ingredient and the low diol ether of ormal weight, in the lysate that obtains, mix water purification.And then, in the mixed liquor that obtains, add water in advance and make its expansible CVP Carbopol ETD2050, add triethanolamine afterwards, prepared the topical composition of embodiment 1-6～1-14.

The topical composition of embodiment 1-6～1-14 has all demonstrated the percutaneous absorbability of good blended physiologically active ingredient.Especially, during ethoxydiglycol more than mixing 30 weight %, confirmed that the percutaneous absorbability of physiologically active ingredient has obtained further raising.

Table 3

g/100g	Embodiment 1-6	Embodiment 1-7	Embodiment 1-8	Embodiment 1-9	Embodiment 1-10	Embodiment 1-11	Embodiment 1-12	Embodiment 1-13	Embodiment 1-14
g/100g	Embodiment 1-6	Embodiment 1-7	Embodiment 1-8	Embodiment 1-9	Embodiment 1-10	Embodiment 1-11	Embodiment 1-12	Embodiment 1-13	Embodiment 1-14	Hydrogenated soya phosphatide matter ※ 1	5	1	10	0.1	-	-	-	-	-
Soybean phospholipid matter ※ 2	-	-	-	-	4	1	8	0.01	8	Hydrogenated soya phosphatide matter ※ 1	5	1	10	0.1	-	-	-	-	-
Soybean phospholipid matter ※ 2	-	-	-	-	4	1	8	0.01	8	Ethoxydiglycol	40	25	50	30	40	25	50	30	30
The retinol cetylate	0.1	-	-	-	-	-	-	-	-	Ethoxydiglycol	40	25	50	30	40	25	50	30	30
The retinol cetylate	0.1	-	-	-	-	-	-	-	-	Arbutin	-	3	-	-	-	-	-	-	-
Tocopheryl acetate	-	-	0.2	-	-	-	-	-	-	Arbutin	-	3	-	-	-	-	-	-	-
Tocopheryl acetate	-	-	0.2	-	-	-	-	-	-	Nicotinic amine	-	-	-	1	-	-	-	-	-
Lignocaine	-	-	-	-	2	-	-	-	-	Nicotinic amine	-	-	-	1	-	-	-	-	-
Lignocaine	-	-	-	-	2	-	-	-	-	Prednisolone valerate acetate	-	-	-	-	-	1.5	-	-	-
Indomethacin	-	-	-	-	-	-	3.75	-	-	Prednisolone valerate acetate	-	-	-	-	-	1.5	-	-	-
Indomethacin	-	-	-	-	-	-	3.75	-	-	Felbinac	-	-	-	-	-	-	-	3	-
Caffeine	-	-	-	-	-	-	-	-	2	Felbinac	-	-	-	-	-	-	-	3	-
Caffeine	-	-	-	-	-	-	-	-	2	CVP Carbopol ETD2050	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Triethanolamine	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	CVP Carbopol ETD2050	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Triethanolamine	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	Water purification	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus

※ 1:SLP-PC92H (iodine number is below 45); Tsuji System oil society makes

※ 2: ベイシス LS-60H (iodine number is below 10); Day, clear オイリオ society made

Test routine 1-4

According to the prescription shown in the table 4, the preparation topical composition.Specifically, with the dissolving of heating of phospholipid, each physiologically active ingredient, low diol ether, three 2 ethyl hexanoic acid glyceride and the polyhydric alcohol of ormal weight, in the lysate that obtains, mix the water purification of heating in addition.And then, in the mixed liquor that obtains, add water in advance and make its expansible CVP Carbopol ETD2050, add triethanolamine afterwards, prepared the topical composition of embodiment 1-15～1-18.

The topical composition of embodiment 1-15～1-18 has all demonstrated the percutaneous absorbability of good physiologically active ingredient.

Table 4

g/100g	Embodiment 1-15	Embodiment 1-16	Embodiment 1-17	Embodiment 1-18
g/100g	Embodiment 1-15	Embodiment 1-16	Embodiment 1-17	Embodiment 1-18	Hydrogenated soya phosphatide matter ※	5	1	10	0.1
Ethoxydiglycol	22	25	50	30	Hydrogenated soya phosphatide matter ※	5	1	10	0.1
Ethoxydiglycol	22	25	50	30	The retinol cetylate	0.1	-	-	-
Arbutin	-	3	-	-	The retinol cetylate	0.1	-	-	-
Arbutin	-	3	-	-	Tocopheryl acetate	-	-	0.2	-
Nicotinic amine	-	-	-	1	Tocopheryl acetate	-	-	0.2	-
Nicotinic amine	-	-	-	1	Glycerol	5	5	5	5
Three 2 ethyl hexanoic acid glyceride	5	5	5	5	Glycerol	5	5	5	5
Three 2 ethyl hexanoic acid glyceride	5	5	5	5	CVP Carbopol ETD2050	0.5	0.5	0.5	0.5
Triethanolamine	In right amount	In right amount	In right amount	In right amount	CVP Carbopol ETD2050	0.5	0.5	0.5	0.5
Triethanolamine	In right amount	In right amount	In right amount	In right amount	Water purification	Surplus	Surplus	Surplus	Surplus

※ レシノ one Le S-10E (iodine number is below 10); Daylight ケミカ Le ズ society makes

Test routine 1-5

According to the prescription shown in the table 5, the preparation topical composition.Specifically; with the dissolving of heating of three (capryl/capric acid) the glyceride solution of the phospholipid of ormal weight, surfactant, d-δ-Wei A fertility alcohol ester and low diol ether; in the lysate that obtains, mix the water purification of heating in addition, prepared the topical composition (any all is the lipid build) of embodiment 1-19 and comparative example 1-4.For each topical composition, vessel side at the Franz of longitudinal type diffusion cell (radius 0.75cm) adds phosphate buffer (pH7.4) 10ml, the holostrome skin of the removal fat of nude mouse (system: HR-1,7 week ages, male) is fixed between the diffusion cell, adds above-mentioned topical composition 1ml in the donor side afterwards.Topical composition had taken off holostrome skin after adding 24 hours from diffusion cell.Clean the surface of the holostrome skin that obtains with water purification and ethyl acetate, make holostrome skin histology homogenate afterwards, with ethyl acetate extraction d-δ-Wei A of containing in the holostrome skin give birth to alcohol ester.Remove after the processing such as albumen, neutralization, gel filtration, centrifugalize, carried out quantitatively for the amount of extraction d-δ-Wei A fertility alcohol ester by HPLC.

The result is as shown in table 5.In table 5, hold allowance (μ g/cm ²) be illustrated in after topical composition added 24 hours, hold the every 1cm of holostrome skin that stays nude mouse ²The amount (μ g) of d-δ-Wei A fertility alcohol ester.

Table 5

g/100g	Embodiment 1-19	Comparative example 1-4
g/100g	Embodiment 1-19	Comparative example 1-4	Hydrogenated soya phosphatide matter ※	1	-
D-δ-Wei A gives birth to alcohol ester	0.25	0.25	Hydrogenated soya phosphatide matter ※	1	-
D-δ-Wei A gives birth to alcohol ester	0.25	0.25	Ethoxydiglycol	28	28
Polyoxyethylene solidifies Oleum Ricini 60	-	0.1	Ethoxydiglycol	28	28
Polyoxyethylene solidifies Oleum Ricini 60	-	0.1	Three (capryl/capric acid) glyceride	2.25	2.25
Water purification	Surplus	Surplus	Three (capryl/capric acid) glyceride	2.25	2.25
Water purification	Surplus	Surplus	Hold allowance (μ g/cm ²)	24.3	5.0

※ SLP-PC92H (iodine number is below 45); Tsuji System oil society makes

Compare with the topical composition of the comparative example 1-4 of mixed surfactant, the topical composition of the embodiment 1-19 of mixed phosphatide matter, the allowance of holding of d-δ-Wei A fertility alcohol ester significantly rises to 4.9 times.Need to prove, because d-δ-Wei A fertility alcohol ester is insoluble in phosphate buffer, so in the benzene test, will hold the amount of staying Intradermal index through angleplied laminate as the Transdermal absorption amount.

Test routine 1-6

According to the prescription shown in the table 6, the preparation topical composition.Specifically, with the dissolving of heating of phospholipid, low diol ether and the polyhydric alcohol of ormal weight, in the lysate that obtains, mix the caffeine aqueous solution of heating in addition, prepared the topical composition (any all is the lipid build) of embodiment 1-20～1-23 and comparative example 1-5～1-6.For each topical composition, vessel side at the Franz of longitudinal type diffusion cell adds phosphate buffer (pH7.4) 10ml, the holostrome skin of the removal fat of nude mouse (system: HR-1,7 week ages, male) is fixed between the diffusion cell, adds above-mentioned topical composition 1ml in the donor side afterwards.Add after 30 hours, carried out quantitatively for the caffeine concentration in the phosphate buffer of vessel side by HPLC.

The result is as shown in table 6.In table 6, transit dose (μ g/cm ²) be illustrated in after topical composition added 30 hours, see through the every 1cm of holostrome skin of nude mouse ²The amount (μ g) of caffeine.

Table 6

g/100g	Embodiment 1-20	Embodiment 1-21	Embodiment 1-22	Embodiment 1-23	Comparative example 1-5	Comparative example 1-6
g/100g	Embodiment 1-20	Embodiment 1-21	Embodiment 1-22	Embodiment 1-23	Comparative example 1-5	Comparative example 1-6	Hydrogenated soya phosphatide matter ※ 1	5	1	-	-	1	1
Soybean phospholipid matter ※ 2	-	-	1	-	-	-	Hydrogenated soya phosphatide matter ※ 1	5	1	-	-	1	1
Soybean phospholipid matter ※ 2	-	-	1	-	-	-	Soybean phospholipid matter ※ 3	-	-	-	1	-	-
Caffeine	2	2	2	2	2	2	Soybean phospholipid matter ※ 3	-	-	-	1	-	-
Caffeine	2	2	2	2	2	2	Ethoxydiglycol	49	49	49	49	-	-
1,3 butylene glycol	-	-	-	-	49	-	Ethoxydiglycol	49	49	49	49	-	-
1,3 butylene glycol	-	-	-	-	49	-	Water purification	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus
Transit dose (μ g/cm ²)	3893	1599	7626	6987	432	122	Water purification	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus

※ 1:SLP-PC92H (iodine number is below 45); Tsuji System oil society makes

※ 2:SLP-PC92; Tsuji System oil society makes

※ 3:SLP-ホワイト; Tsuji System oil society makes

Compare with the topical composition of the comparative example 1-5 that mixes 1,3 butylene glycol, mix the topical composition of the embodiment 1-21 of ethoxydiglycol, its transit dose has demonstrated 3.8 times of high values.In addition, from the result of the topical composition of comparative example 1-6 as can be seen, only utilize the Transdermal absorption effect of hydrogenated soya phosphatide matter not high.

And then, from the result of the topical composition of embodiment 1-22 and 1-23 as can be seen, by use unhydrided soybean phospholipid matter as lipid, transit dose further can be increased to more than 4 times of topical composition of embodiment 1-21, show good especially Transdermal absorption effect.

Test routine 1-7

According to the prescription shown in the table 7, the preparation topical composition.Specifically, with the dissolving of heating of phospholipid, coenzyme Q10, three 2 ethyl hexanoic acid glyceride and the low diol ether of ormal weight or glycerol, in the lysate that obtains, mix the water purification of heating in addition.And then, in the mixed liquor that obtains, mix other compositions of aequum, prepared the topical composition (any all is the lipid build) of embodiment 1-24～1-26 and comparative example 1-7.For each topical composition, vessel side at the Franz of longitudinal type diffusion cell (radius 0.75cm) adds three-2 ethyl hexanoic acid glyceride 10ml, the holostrome skin of the removal fat of nude mouse (system: HR-1,7 week ages, male) is fixed between the diffusion cell, adds above-mentioned topical composition 2g in the donor side afterwards.Topical composition added after 2 hours, took off holostrome skin from diffusion cell.Clean the surface of the holostrome skin that obtains with water purification and ethyl acetate, make holostrome skin histology homogenate afterwards, with ethyl acetate extraction the coenzyme Q10 that contains in the holostrome skin.Carried out quantitatively for the amount of the coenzyme Q10 in the extract that obtains by HPLC.

The result is as shown in table 7.In table 7, hold allowance (μ g/cm ²) be illustrated in after topical composition added 2 hours, hold the every 1cm of holostrome skin that stays nude mouse ²The amount (μ g) of coenzyme Q10.

Table 7

g/100g	Embodiment 1-24	Embodiment 1-25	Embodiment 1-26	Comparative example 1-7
g/100g	Embodiment 1-24	Embodiment 1-25	Embodiment 1-26	Comparative example 1-7	Partially hydrogenated soybean lecithin ^*1	1	-	-	-
Hydrogenated soy phosphatidyl choline ^*2	-	1	-	1	Partially hydrogenated soybean lecithin ^*1	1	-	-	-
Hydrogenated soy phosphatidyl choline ^*2	-	1	-	1	Soybean lecithin ^*3	-	-	1	-
Ethoxydiglycol	69	69	69	-	Soybean lecithin ^*3	-	-	1	-
Ethoxydiglycol	69	69	69	-	Coenzyme Q10	0.03	0.03	0.03	0.03
Glycerol	-	-	-	69	Coenzyme Q10	0.03	0.03	0.03	0.03
Glycerol	-	-	-	69	Three 2 ethyl hexanoic acid glyceride	2.97	2.97	2.97	2.97
Water purification	In right amount	In right amount	In right amount	In right amount	Three 2 ethyl hexanoic acid glyceride	2.97	2.97	2.97	2.97
Water purification	In right amount	In right amount	In right amount	In right amount	Hold allowance (μ g/cm ²)	1.58	0.89	2.10	0.25

※ 1:SLP-PC92H (iodine number is below 45); Tsuji System oil society makes

※ 2:SLP-PC70; Tsuji System oil society makes

※ 3: レシノ one Le S-10E (iodine number is below 10); Daylight ケミカ Le ズ society makes

Compare with the topical composition of the comparative example 1-7 that mixes glycerol, mix the topical composition of the embodiment 1-24～1-26 of ethoxydiglycol, the allowance of holding of its coenzyme Q10 has demonstrated 3.6～8.4 times of remarkable high values.In addition, can confirm the lecithin that hydrogenation degree is low, further improve the percutaneous absorbability of coenzyme Q10.

Test routine 1-8

According to the prescription shown in the table 8, the preparation topical composition.Specifically, with the dissolving of heating of three (capryl/capric acid) the glyceride solution of the phospholipid of ormal weight, d-δ-Wei A fertility alcohol ester and low diol ether, the water purification that mixing is heated in addition in the lysate that obtains.And then, in the mixed liquor that obtains, add water in advance and make its expansible CVP Carbopol ETD2050, add triethanolamine afterwards, prepared the topical composition of embodiment 1-27～1-36.

The topical composition of embodiment 1-27～1-36 has all demonstrated the percutaneous absorbability that good d-δ-Wei A gives birth to alcohol ester.Wherein, be 25～80% in the mixed proportion of ethoxydiglycol, particularly in 30～70% the topical composition, confirmed that the percutaneous absorbability of d-δ-Wei A fertility alcohol ester has obtained further raising.

Table 8

g/100g	Embodiment 1-27	Embodiment 1-28	Embodiment 1-29	Embodiment 1-30	Embodiment 1-31	Embodiment 1-32	Embodiment 1-33	Embodiment 1-34	Embodiment 1-35	Embodiment 1-36
g/100g	Embodiment 1-27	Embodiment 1-28	Embodiment 1-29	Embodiment 1-30	Embodiment 1-31	Embodiment 1-32	Embodiment 1-33	Embodiment 1-34	Embodiment 1-35	Embodiment 1-36	Soybean phospholipid matter ※	0.1	8	0.1	8	0.1	8	0.1	8	0.1	8
Ethoxydiglycol	22	22	25	25	30	30	70	70	80	80	Soybean phospholipid matter ※	0.1	8	0.1	8	0.1	8	0.1	8	0.1	8
Ethoxydiglycol	22	22	25	25	30	30	70	70	80	80	D-δ-Wei A gives birth to alcohol ester	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25
Three (capryl/capric acid) glyceride	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25	D-δ-Wei A gives birth to alcohol ester	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25
Three (capryl/capric acid) glyceride	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25	CVP Carbopol ETD2050	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Triethanolamine	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	CVP Carbopol ETD2050	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Triethanolamine	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	Water purification	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus

※ SLP-PC70; Tsuji System oil society makes

Test routine 1-9

According to the prescription shown in the table 9, the preparation topical composition.Specifically, with the dissolving of heating of phospholipid, coenzyme Q10, three 2 ethyl hexanoic acid glyceride and the low diol ether of ormal weight, in the lysate that obtains, mix the water purification of heating in addition.And then, in the mixed liquor that obtains, add water in advance and make its expansible CVP Carbopol ETD2050, add triethanolamine afterwards, prepared the topical composition of embodiment 1-37～1-46.

The topical composition of embodiment 1-37～1-46 has all demonstrated the percutaneous absorbability of good blended coenzyme Q10.Wherein, be 25～80% in the mixed proportion of ethoxydiglycol, particularly in 30～70% the topical composition, confirmed that the percutaneous absorbability of coenzyme Q10 has obtained further raising.

Table 9

g/100g	Embodiment 1-37	Embodiment 1-38	Embodiment 1-39	Embodiment 1-40	Embodiment 1-41	Embodiment 1-42	Embodiment 1-43	Embodiment 1-44	Embodiment 1-45	Embodiment 1-46
g/100g	Embodiment 1-37	Embodiment 1-38	Embodiment 1-39	Embodiment 1-40	Embodiment 1-41	Embodiment 1-42	Embodiment 1-43	Embodiment 1-44	Embodiment 1-45	Embodiment 1-46	Soybean phospholipid matter ※	0.1	8	0.1	8	0.1	8	0.1	8	0.1	8
Ethoxydiglycol	22	22	25	25	30	30	70	70	80	80	Soybean phospholipid matter ※	0.1	8	0.1	8	0.1	8	0.1	8	0.1	8
Ethoxydiglycol	22	22	25	25	30	30	70	70	80	80	Coenzyme Q10	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
Three 2 ethyl hexanoic acid glyceride	2.97	2.97	2.97	2.97	2.97	2.97	2.97	2.97	2.97	2.97	Coenzyme Q10	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
Three 2 ethyl hexanoic acid glyceride	2.97	2.97	2.97	2.97	2.97	2.97	2.97	2.97	2.97	2.97	CVP Carbopol ETD2050	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Triethanolamine	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	CVP Carbopol ETD2050	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Triethanolamine	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	Water purification	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus

※ SLP-PC70; Tsuji System oil society makes

Test routine 2-1

According to the prescription shown in the table 10, the preparation topical composition.Specifically; the phospholipid of ormal weight, three (capryl/capric acid) glyceride solution, low diol ether and the polyhydric alcohol of d-δ-Wei A fertility alcohol ester are dissolved; in the lysate that obtains, mix the water purification of heating in addition, prepared the topical composition (any all is the lipid build) of embodiment 2-1 and comparative example 2-1.For each topical composition, utilize identical method with above-mentioned test example 1-5, estimated the percutaneous absorbability of d-δ-Wei A fertility alcohol ester.Its result is as shown in table 10.

Table 10

g/100g	Embodiment 2-1	Comparative example 2-1
g/100g	Embodiment 2-1	Comparative example 2-1	Hydrogenated soya phosphatide matter ^*	1	-
D-δ-Wei A gives birth to alcohol ester	0.25	0.25	Hydrogenated soya phosphatide matter ^*	1	-
D-δ-Wei A gives birth to alcohol ester	0.25	0.25	Ethoxydiglycol	5	-
1,3 butylene glycol	38.8	-	Ethoxydiglycol	5	-
1,3 butylene glycol	38.8	-	Dipropylene glycol	-	43.8
Three (capryl/capric acid) glyceride	2.25	2.25	Dipropylene glycol	-	43.8
Three (capryl/capric acid) glyceride	2.25	2.25	Water purification	Surplus	Surplus
Hold allowance (μ g/cm ²)	0.33	0.11	Water purification	Surplus	Surplus

※ SLP-PC92H (iodine number is below 45); Tsuji System oil society makes

Compare with the topical composition of comparative example 2-1, the topical composition of embodiment 2-1, the allowance of holding of its d-δ-Wei A fertility alcohol ester has demonstrated 3 times of high values.Because d-δ-Wei A fertility alcohol ester is insoluble in phosphate buffer, so will hold the amount of the staying Intradermal index as the Transdermal absorption amount through angleplied laminate in this test.

Test routine 2-2

According to the prescription shown in the table 11, the preparation topical composition.Specifically; the phospholipid of ormal weight, three (capryl/capric acid) glyceride solution, VC-IP, coenzyme Q10, low diol ether and the polyhydric alcohol of d-δ-Wei A fertility alcohol ester are dissolved, in the lysate that obtains, mix the water purification of heating in addition.In the mixture that obtains, further add water in advance and make that it is expansible (copolymer of third rare acyl dimethyl taurine ammonium/VP) has prepared the topical composition of embodiment 2-2～2-5.

The topical composition of embodiment 2-2～2-5, the percutaneous absorbability of blended physiologically active ingredient all good.

Table 11

g/100g	Embodiment 2-2	Embodiment 2-3	Embodiment 2-4	Embodiment 2-5
g/100g	Embodiment 2-2	Embodiment 2-3	Embodiment 2-4	Embodiment 2-5	Hydrogenated soya phosphatide matter ^*	1	5	1	1
Ethoxydiglycol	5	6	5	6	Hydrogenated soya phosphatide matter ^*	1	5	1	1
Ethoxydiglycol	5	6	5	6	1,3 butylene glycol	40	-	40	-
Dipropylene glycol	-	39	-	39	1,3 butylene glycol	40	-	40	-
Dipropylene glycol	-	39	-	39	D-δ-Wei A gives birth to alcohol ester	0.25	0.5	-	-
VC-IP	1	1	-	-	D-δ-Wei A gives birth to alcohol ester	0.25	0.5	-	-
VC-IP	1	1	-	-	Coenzyme Q10	-	-	0.03	0.03
Three (capryl/capric acid) glyceride	2.25	4.5	-	-	Coenzyme Q10	-	-	0.03	0.03
Three (capryl/capric acid) glyceride	2.25	4.5	-	-	(the copolymer of third rare acyl dimethyl taurine ammonium/VP)	1	1	1	1
Water purification	Surplus	Surplus	Surplus	Surplus		1	1	1	1

^*SLP-PC92H (iodine number is below 45); Tsuji System oil society makes

Test routine 2-3

According to the prescription shown in table 12 and the table 13, the preparation topical composition.Specifically, phospholipid, physiologically active ingredient, low diol ether, three 2 ethyl hexanoic acid glyceride and the polyhydric alcohol with ormal weight dissolves the water purification that mixing is heated in addition in the lysate that obtains.And then, in the mixture that obtains, further add water in advance and make its expansible CVP Carbopol ETD2050, add triethanolamine afterwards, prepared the topical composition of embodiment 2-6～2-18.

Its result, phospholipid is in the scope of 0.01～8 weight %, and ethoxydiglycol is at the topical composition of the embodiment of the scope of 0.01～6.5 weight % 2-6～2-18, the percutaneous absorbability of blended physiologically active ingredient all good.

Table 12

g/100g	Embodiment 2-6	Embodiment 2-7	Embodiment 2-8	Embodiment 2-9	Embodiment 2-10	Embodiment 2-11	Embodiment 2-12	Embodiment 2-13	Embodiment 2-14
g/100g	Embodiment 2-6	Embodiment 2-7	Embodiment 2-8	Embodiment 2-9	Embodiment 2-10	Embodiment 2-11	Embodiment 2-12	Embodiment 2-13	Embodiment 2-14	Hydrogenated soya phosphatide matter ※ 1	4	1	8	0.01	-	-	-	-	-
Soybean phospholipid matter ※ 2	-	-	-	-	4	1	8	0.01	8	Hydrogenated soya phosphatide matter ※ 1	4	1	8	0.01	-	-	-	-	-
Soybean phospholipid matter ※ 2	-	-	-	-	4	1	8	0.01	8	Ethoxydiglycol	3	1	6.5	0.1	6.5	3	1	0.1	6
The retinol cetylate	0.1	-	-	-	-	-	-	-	-	Ethoxydiglycol	3	1	6.5	0.1	6.5	3	1	0.1	6
The retinol cetylate	0.1	-	-	-	-	-	-	-	-	Arbutin	-	3	-	-	-	-	-	-	-
Tocopheryl acetate	-	-	0.2	-	-	-	-	-	-	Arbutin	-	3	-	-	-	-	-	-	-
Tocopheryl acetate	-	-	0.2	-	-	-	-	-	-	Nicotinic amine	-	-	-	1	-	-	-	-	-
Lignocaine	-	-	-	-	2	-	-	-	-	Nicotinic amine	-	-	-	1	-	-	-	-	-
Lignocaine	-	-	-	-	2	-	-	-	-	Prednisolone valerate acetate	-	-	-	-	-	1.5	-	-	-
Indomethacin	-	-	-	-	-	-	3.75	-	-	Prednisolone valerate acetate	-	-	-	-	-	1.5	-	-	-
Indomethacin	-	-	-	-	-	-	3.75	-	-	Felbinac	-	-	-	-	-	-	-	3	-
Caffeine	-	-	-	-	-	-	-	-	2	Felbinac	-	-	-	-	-	-	-	3	-
Caffeine	-	-	-	-	-	-	-	-	2	1,3 butylene glycol	10	10	10	10	10	10	10	10	10
CVP Carbopol ETD2050	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	1,3 butylene glycol	10	10	10	10	10	10	10	10	10
CVP Carbopol ETD2050	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	Triethanolamine	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount
Water purification	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Triethanolamine	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount

※ 1:SLP-PC92H (iodine number is below 45); Tsuji System oil society makes

Table 13

	Embodiment 2-15	Embodiment 2-16	Embodiment 2-17	Embodiment 2-18
	Embodiment 2-15	Embodiment 2-16	Embodiment 2-17	Embodiment 2-18	Hydrogenated soya phosphatide matter ※	4	1	8	0.01
Ethoxydiglycol	6.5	3	1	0.1	Hydrogenated soya phosphatide matter ※	4	1	8	0.01
Ethoxydiglycol	6.5	3	1	0.1	The retinol cetylate	0.1	-	-	-
Arbutin	-	7	-	-	The retinol cetylate	0.1	-	-	-
Arbutin	-	7	-	-	Tocopheryl acetate	-	-	0.5	-
Nicotinic amine	-	-	-	1	Tocopheryl acetate	-	-	0.5	-
Nicotinic amine	-	-	-	1	1,3 butylene glycol	10	10	10	10
Three 2 ethyl hexanoic acid glyceride	10	10	10	10	1,3 butylene glycol	10	10	10	10
Three 2 ethyl hexanoic acid glyceride	10	10	10	10	CVP Carbopol ETD2050	0.5	0.5	0.5	0.5
Triethanolamine	In right amount	In right amount	In right amount	In right amount	CVP Carbopol ETD2050	0.5	0.5	0.5	0.5
Triethanolamine	In right amount	In right amount	In right amount	In right amount	Water purification	Surplus	Surplus	Surplus	Surplus

Test routine 2-4

According to the prescription shown in the table 14, the preparation topical composition.Specifically, with the dissolving of heating of phospholipid, low diol ether and the polyhydric alcohol of ormal weight, in the lysate that obtains, mix the caffeine aqueous solution of heating in addition, prepared the topical composition (lipid build) of embodiment 2-19 and comparative example 2-2～2-3.For each topical composition, estimated the percutaneous absorbability of caffeine by the method identical with the routine 1-6 of test.Its result is as shown in table 14.

Table 14

g/100g	Embodiment 2-19	Comparative example 2-2	Comparative example 2-3
g/100g	Embodiment 2-19	Comparative example 2-2	Comparative example 2-3	Hydrogenated soya phosphatide matter ※	1	1	1
Caffeine	2	2	2	Hydrogenated soya phosphatide matter ※	1	1	1
Caffeine	2	2	2	Ethoxydiglycol	5	-	-
1,3 butylene glycol	44	49	-	Ethoxydiglycol	5	-	-
1,3 butylene glycol	44	49	-	Water purification	Surplus	Surplus	Surplus
Transit dose (μ g/cm ²)	652	423	122	Water purification	Surplus	Surplus	Surplus

※ SLP-PC92H (iodine number is below 45); Tsuji System oil society makes

Compare with the topical composition of the comparative example 2-2 that uses 1,3 butylene glycol, mixed the topical composition of the embodiment 2-19 of ethoxydiglycol, its transit dose rises to more than 1.5 times.In addition, from the result of the topical composition of comparative example 2-3 as can be seen, only utilize the Transdermal absorption effect of hydrogenated soya phosphatide matter not high.

Test routine 2-5

According to the prescription shown in table 15 and the table 16, the preparation topical composition.Specifically, with the dissolving of heating of three (capryl/capric acid) glyceride solution, low diol ether and the polyhydric alcohol of the phospholipid of ormal weight, d-δ-Wei A fertility alcohol ester, the water purification that mixing is heated in addition in the lysate that obtains.And then, in the mixed liquor that obtains, further add water in advance and make its expansible CVP Carbopol ETD2050, add triethanolamine afterwards, prepared the topical composition of embodiment 2-20～2-33.

The topical composition of embodiment 2-20～2-33, the percutaneous absorbability of blended d-δ-Wei A fertility alcohol ester all good.Wherein, the mixed proportion of phospholipid is 0.1～7.5 weight %, and the mixed proportion of ethoxydiglycol is that the percutaneous absorbability of d-δ-Wei A fertility alcohol ester of 0.1～6 weight % is good.Especially, the mixed proportion of phospholipid is 1～7 weight %, and the mixed proportion of ethoxydiglycol is that the percutaneous absorbability of d-δ-Wei A fertility alcohol ester of 1～5 weight % is good.

Table 15

g/100g	Embodiment 2-20	Embodiment 2-21	Embodiment 2-22	Embodiment 2-23	Embodiment 2-24	Embodiment 2-25	Embodiment 2-26
g/100g	Embodiment 2-20	Embodiment 2-21	Embodiment 2-22	Embodiment 2-23	Embodiment 2-24	Embodiment 2-25	Embodiment 2-26	Soybean phospholipid matter ※	4	4	4	4	4	4	4
Ethoxydiglycol	0.01	0.1	1	3	5	6	6.5	Soybean phospholipid matter ※	4	4	4	4	4	4	4
Ethoxydiglycol	0.01	0.1	1	3	5	6	6.5	D-δ-Wei A gives birth to alcohol ester	0.25	0.25	0.25	0.25	0.25	0.25	0.25
Glycerol	3	3	3	3	3	3	3	D-δ-Wei A gives birth to alcohol ester	0.25	0.25	0.25	0.25	0.25	0.25	0.25
Glycerol	3	3	3	3	3	3	3	Three (capryl/capric acid) glyceride	2.25	2.25	2.25	2.25	2.25	2.25	2.25
CVP Carbopol ETD2050	0.5	0.5	0.5	0.5	0.5	0.5	0.5	Three (capryl/capric acid) glyceride	2.25	2.25	2.25	2.25	2.25	2.25	2.25
CVP Carbopol ETD2050	0.5	0.5	0.5	0.5	0.5	0.5	0.5	Triethanolamine	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount
Water purification	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Triethanolamine	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount

※ SLP-PC70; Tsuji System oil society makes

Table 16

g/100g	Embodiment 2-27	Embodiment 2-28	Embodiment 2-29	Embodiment 2-30	Embodiment 2-31	Embodiment 2-32	Embodiment 2-33
g/100g	Embodiment 2-27	Embodiment 2-28	Embodiment 2-29	Embodiment 2-30	Embodiment 2-31	Embodiment 2-32	Embodiment 2-33	Soybean phospholipid matter ※	0.01	0.1	1	4	7	7.5	8
Ethoxydiglycol	5	5	5	5	5	5	5	Soybean phospholipid matter ※	0.01	0.1	1	4	7	7.5	8
Ethoxydiglycol	5	5	5	5	5	5	5	D-δ-Wei A gives birth to alcohol ester	0.25	0.25	0.25	0.25	0.25	0.25	0.25
Glycerol	3	3	3	3	3	3	3	D-δ-Wei A gives birth to alcohol ester	0.25	0.25	0.25	0.25	0.25	0.25	0.25
Glycerol	3	3	3	3	3	3	3	Three (capryl/capric acid) glyceride	2.25	2.25	2.25	2.25	2.25	2.25	2.25
CVP Carbopol ETD2050	0.5	0.5	0.5	0.5	0.5	0.5	0.5	Three (capryl/capric acid) glyceride	2.25	2.25	2.25	2.25	2.25	2.25	2.25
CVP Carbopol ETD2050	0.5	0.5	0.5	0.5	0.5	0.5	0.5	Triethanolamine	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount
Water purification	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Triethanolamine	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount

※ SLP-PC70; Tsuji System oil society makes

Test routine 2-6

According to the prescription shown in table 17 and the table 18, the preparation topical composition.Specifically, with the dissolving of heating of phospholipid, coenzyme Q10, three 2 ethyl hexanoic acid glyceride and the low diol ether of ormal weight, in the lysate that obtains, mix the water purification of heating in addition.And then, in the mixed liquor that obtains, further add water in advance and make its expansible CVP Carbopol ETD2050, add triethanolamine afterwards, prepared the topical composition of embodiment 2-34～2-47.

The topical composition of embodiment 2-34～2-47, the percutaneous absorbability of blended coenzyme Q10 all good.Wherein, the mixed proportion of phospholipid is 0.1～7.5 weight %, and the mixed proportion of ethoxydiglycol is that the percutaneous absorbability of coenzyme Q10 of 0.1～6 weight % is good.Especially, the mixed proportion of phospholipid is 1～7 weight %, and the mixed proportion of ethoxydiglycol is that the percutaneous absorbability of coenzyme Q10 of 1～5 weight % is good.

Table 17

g/100g	Embodiment 2-34	Embodiment 2-35	Embodiment 2-36	Embodiment 2-37	Embodiment 2-38	Embodiment 2-39	Embodiment 2-40
g/100g	Embodiment 2-34	Embodiment 2-35	Embodiment 2-36	Embodiment 2-37	Embodiment 2-38	Embodiment 2-39	Embodiment 2-40	Soybean phospholipid matter ※	4	4	4	4	4	4	4
Ethoxydiglycol	0.01	0.1	1	3	5	6	6.5	Soybean phospholipid matter ※	4	4	4	4	4	4	4
Ethoxydiglycol	0.01	0.1	1	3	5	6	6.5	Coenzyme Q10	0.03	0.03	0.03	0.03	0.03	0.03	0.03
Glycerol	3	3	3	3	3	3	3	Coenzyme Q10	0.03	0.03	0.03	0.03	0.03	0.03	0.03
Glycerol	3	3	3	3	3	3	3	Three 2 ethyl hexanoic acid glyceride	2.97	2.97	2.97	2.97	2.97	2.97	2.97
CVP Carbopol ETD2050	0.5	0.5	0.5	0.5	0.5	0.5	0.5	Three 2 ethyl hexanoic acid glyceride	2.97	2.97	2.97	2.97	2.97	2.97	2.97
CVP Carbopol ETD2050	0.5	0.5	0.5	0.5	0.5	0.5	0.5	Triethanolamine	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount
Water purification	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Triethanolamine	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount

※ SLP-PC70; Tsuji System oil society makes

Table 18

g/100g	Embodiment 2-41	Embodiment 2-42	Embodiment 2-43	Embodiment 2-44	Embodiment 2-45	Embodiment 2-46	Embodiment 2-47
g/100g	Embodiment 2-41	Embodiment 2-42	Embodiment 2-43	Embodiment 2-44	Embodiment 2-45	Embodiment 2-46	Embodiment 2-47	Soybean phospholipid matter ※	0.01	0.1	1	4	7	7.5	8
Ethoxydiglycol	5	5	5	5	5	5	5	Soybean phospholipid matter ※	0.01	0.1	1	4	7	7.5	8
Ethoxydiglycol	5	5	5	5	5	5	5	Coenzyme Q10	0.03	0.03	0.03	0.03	0.03	0.03	0.03
Glycerol	3	3	3	3	3	3	3	Coenzyme Q10	0.03	0.03	0.03	0.03	0.03	0.03	0.03
Glycerol	3	3	3	3	3	3	3	Three 2 ethyl hexanoic acid glyceride	2.97	2.97	2.97	2.97	2.97	2.97	2.97
CVP Carbopol ETD2050	0.5	0.5	0.5	0.5	0.5	0.5	0.5	Three 2 ethyl hexanoic acid glyceride	2.97	2.97	2.97	2.97	2.97	2.97	2.97
CVP Carbopol ETD2050	0.5	0.5	0.5	0.5	0.5	0.5	0.5	Triethanolamine	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount
Water purification	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Triethanolamine	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount

※ SLP-PC70; Tsuji System oil society makes

Test routine 3-1

According to the prescription shown in the table 19, the preparation topical composition.Specifically, phospholipid and the low diol ether with ormal weight dissolves the water purification that mixing is heated in addition in the lysate that obtains.And then; in the mixture that obtains; further adding water in advance makes that it is expansible (third rare acyl dimethyl taurine ammonium/VP) copolymer and hyaluronate sodium has prepared the topical composition (embodiment 3-1 and comparative example 3-1 are the lipid build) of embodiment 3-1, comparative example 3-1, reference examples 3.For each topical composition, vessel side at the Franz of longitudinal type diffusion cell (radius 0.75cm) adds phosphate buffer (pH7.4) 10ml, the holostrome skin of the removal fat of nude mouse (system: HR-1,7 week ages, male) is fixed between the diffusion cell, adds above-mentioned topical composition 1ml in the donor side afterwards.Add after 24 hours, take off holostrome skin from diffusion cell.Water and acetone are cleaned the surface of the holostrome skin that obtains, and make holostrome skin histology homogenate afterwards, have extracted the hyaluronic acid that contains in the holostrome skin with water purification.Use hyaluronic acid testing cassete (biochemical industry) to carry out quantitatively for the hyaluronic amount of extraction.Calculated the hyaluronic amount (transit dose: μ g/cm that sees through holostrome skin from the measured value of reference examples 3 ²).Its result is shown in table 19.

Table 19

g/100g	Embodiment 3-1	Comparative example 3-1	Reference examples 3
g/100g	Embodiment 3-1	Comparative example 3-1	Reference examples 3	Partially hydrogenated soybean lecithin (SLP-PC92H)	1	-	-
Ethoxydiglycol	49	49	-	Partially hydrogenated soybean lecithin (SLP-PC92H)	1	-	-
Ethoxydiglycol	49	49	-	Hyaluronate sodium	0.1	0.1	-
(the copolymer of third rare acyl dimethyl taurine ammonium/VP)	0.3	0.3	-	Hyaluronate sodium	0.1	0.1	-
	0.3	0.3	-	Water purification	Surplus	Surplus	100
Hold allowance (μ g/cm ²)	13.6	7.7	3.4	Water purification	Surplus	Surplus	100
Hold allowance (μ g/cm ²)	13.6	7.7	3.4	Transit dose (μ g/cm ²)	10.2	4.3	-

From this result also as can be seen, hyaluronic acid surely be impregnated into skin inside, in the external agent of embodiment 3-1, makes hyaluronic acid be impregnated into skin inside and may become.

Test routine 3-2

According to the prescription shown in the table 20, the preparation topical composition.Specifically, with the dissolving of heating of phospholipid, low diol ether and the polyhydric alcohol of ormal weight, in the lysate that obtains, mix the aqueous ascorbic acid of heating in addition.And then, in the mixture that obtains, further add the required composition of ormal weight, prepared the topical composition (beyond the comparative example 3-4 is the lipid build) of embodiment 3-2～3-4, comparative example 3-2～3-4.For each topical composition, estimated the percutaneous absorbability of ascorbic acid by the method identical with the routine 1-1 of test.Its result is shown in table 20.

Table 20

g/100g	Embodiment 3-2	Embodiment 3-3	Comparative example 3-2	Comparative example 3-3	Comparative example 3-4
g/100g	Embodiment 3-2	Embodiment 3-3	Comparative example 3-2	Comparative example 3-3	Comparative example 3-4	Hydrogenated soya phosphatide matter ^*1	5	-	5	5	-
Soybean phospholipid matter ^*2	-	1	5	5	-	Hydrogenated soya phosphatide matter ^*1	5	-	5	5	-
Soybean phospholipid matter ^*2	-	1	5	5	-	Ascorbic acid	10	20	10	10	20
Ethoxydiglycol	43	49	-	-	53	Ascorbic acid	10	20	10	10	20
Ethoxydiglycol	43	49	-	-	53	Glycerol	-	-	43	-	-
1,3 butylene glycol	-	-	-	43	-	Glycerol	-	-	43	-	-
1,3 butylene glycol	-	-	-	43	-	Oleyl amine	1	1	-	-	-
Two glycerol	-	-	-	-	4	Oleyl amine	1	1	-	-	-
Two glycerol	-	-	-	-	4	Trimethyl glycine	-	-	-	-	3
Water purification	Surplus	Surplus	Surplus	Surplus	Surplus	Trimethyl glycine	-	-	-	-	3
Water purification	Surplus	Surplus	Surplus	Surplus	Surplus	Transit dose (30 hours) μ g/cm ²	1118	6350	359	397	174

^*1 SLP-PC92H (iodine number is below 45); Tsuji System oil society makes

^*2 SLP-PC70; Tsuji System oil society makes

The transit dose of the topical composition of embodiment 3-2 with respect to the topical composition of comparative example 3-2～3-4, has demonstrated high value more than 2.8 times, and then significantly improving with respect to the topical composition of comparative example 3-4 is more than 6.4 times.And then from the result of the topical composition of embodiment 3-3 also as can be seen, by there not being hydrogenant soybean phospholipid matter, the percutaneous absorption type of ascorbic acid further is improved.

Test routine 3-3

According to the prescription shown in the table 21, the preparation topical composition.Specifically; with the dissolving of heating of three (capryl/capric acid) glyceride solution, low diol ether and the polyhydric alcohol of the phospholipid of ormal weight, d-δ-Wei A fertility alcohol ester; in the lysate that obtains, mix the water purification of heating in addition, prepared the topical composition (lipid build) of embodiment 3-4 and comparative example 3-5.For each topical composition, utilize identical method with above-mentioned test example 1-5, estimated the percutaneous absorbability of d-δ-Wei A fertility alcohol ester.Its result is shown in table 21.

Table 21

g/100g	Embodiment 3-4	Comparative example 3-5
g/100g	Embodiment 3-4	Comparative example 3-5	Hydrogenated soya phosphatide matter ^*	1	1
D-δ-Wei A gives birth to alcohol ester	0.25	0.25	Hydrogenated soya phosphatide matter ^*	1	1
D-δ-Wei A gives birth to alcohol ester	0.25	0.25	Ethoxydiglycol	5	-
1,3 butylene glycol	38.8	-	Ethoxydiglycol	5	-
1,3 butylene glycol	38.8	-	Dipropylene glycol	-	43.8
Three (capryl/capric acid) glyceride	2.25	2.25	Dipropylene glycol	-	43.8
Three (capryl/capric acid) glyceride	2.25	2.25	Water purification	Surplus	Surplus
Hold allowance (μ g/cm ²)	0.33	0.11	Water purification	Surplus	Surplus

^*SLP-PC92H (iodine number is below 45); Tsuji System oil society makes

Compare with the topical composition of the comparative example 3-5 that has mixed dipropylene glycol, mixed the topical composition of the embodiment 3-4 of ethoxydiglycol, it holds allowance is 3 times, and percutaneous absorption type is significantly improved.

Test routine 3-4

According to the prescription shown in the table 22, the preparation topical composition.Specifically; the phospholipid of ormal weight, three (capryl/capric acid) glyceride solution, glycol ethers and the polyhydric alcohol of d-δ-Wei A fertility alcohol ester are dissolved; in the lysate that obtains, mix the water purification of heating in addition, prepared the topical composition (lipid build) of embodiment 3-5 and comparative example 3-6.For each topical composition, utilize identical method with above-mentioned test example 1-5, estimated the percutaneous absorbability of d-δ-Wei A fertility alcohol ester.Its result is shown in table 22.In table 22, hold allowance (μ g/cm ²) be illustrated in after topical composition added 24 hours, hold the every 1cm of holostrome skin that stays nude mouse ²The amount (μ g) of d-δ-Wei A fertility alcohol ester.

Table 22

g/100g	Embodiment 3-5	Comparative example 3-6
g/100g	Embodiment 3-5	Comparative example 3-6	Hydrogenated soya phosphatide matter ※	1	-
D-δ-Wei A gives birth to alcohol ester	0.25	0.25	Hydrogenated soya phosphatide matter ※	1	-
D-δ-Wei A gives birth to alcohol ester	0.25	0.25	Ethoxydiglycol	28	28
Polyoxyethylene solidifies Oleum Ricini 60	-	0.1	Ethoxydiglycol	28	28
Polyoxyethylene solidifies Oleum Ricini 60	-	0.1	Three (capryl/capric acid) glyceride	2.25	2.25
Water purification	Surplus	Surplus	Three (capryl/capric acid) glyceride	2.25	2.25
Water purification	Surplus	Surplus	Hold allowance (μ g/cm ²)	24.3	5.0

※ SLP-PC92H (iodine number is below 45); Tsuji System oil society makes

Compare with the topical composition of comparative example 3-6, mixed the topical composition of the embodiment 3-5 of phospholipid, it holds that allowance significantly improves is 4.9 times.

Test routine 3-5

According to the prescription shown in the table 23, the preparation topical composition.Specifically, with the dissolving of heating of phospholipid, low diol ether and the polyhydric alcohol of ormal weight, in the lysate that obtains, mix the caffeine aqueous solution of heating in addition, prepared the topical composition (any all is the lipid build) of embodiment 3-6～3-10 and comparative example 3-7～3-8.For each topical composition, utilize identical method with above-mentioned test example 1-6, estimated the percutaneous absorbability of caffeine.Its result is shown in table 23.

Table 23

g/100g	Embodiment 3-6	Embodiment 3-7	Embodiment 3-8	Embodiment 3-9	Embodiment 3-10	Comparative example 3-7	Comparative example 3-8
g/100g	Embodiment 3-6	Embodiment 3-7	Embodiment 3-8	Embodiment 3-9	Embodiment 3-10	Comparative example 3-7	Comparative example 3-8	Hydrogenated soya phosphatide matter ※ 1	5	1	-	-	1	1	1
Soybean phospholipid matter ※ 2	-	-	1	-	-	-	-	Hydrogenated soya phosphatide matter ※ 1	5	1	-	-	1	1	1
Soybean phospholipid matter ※ 2	-	-	1	-	-	-	-	Soybean phospholipid matter ※ 3	-	-	-	1	1	-	-
Caffeine	2	2	2	2	2	2	2	Soybean phospholipid matter ※ 3	-	-	-	1	1	-	-
Caffeine	2	2	2	2	2	2	2	Ethoxydiglycol	49	49	49	49	5	-	-
1,3 butylene glycol	-	-	-	-	44	49	-	Ethoxydiglycol	49	49	49	49	5	-	-
1,3 butylene glycol	-	-	-	-	44	49	-	Water purification	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus
Transit dose (μ g/cm ²)	3893	1599	7626	6987	652	432	122	Water purification	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus

※ 1:SLP-PC92H (iodine number is below 45); Tsuji System oil society makes

※ 2:SLP-PC92; Tsuji System oil society makes

※ 3:SLP-ホワイト; Tsuji System oil society makes

Compare with the topical composition of the comparative example 3-7 that has mixed 1,3 butylene glycol, mixed the topical composition of the embodiment 3-7 of ethoxydiglycol, it is 3.8 times that its transit dose significantly improves.In addition, from the result of the topical composition of comparative example 3-8 as can be seen, only utilize the Transdermal absorption effect of hydrogenated soya phosphatide matter not high.

And then, from the result of the topical composition of embodiment 3-8 and 3-9 as can be seen, use unhydrided soybean phospholipid matter, can significantly increase transit dose.

Test routine 3-6

Topical composition (the embodiment 3-11～3-32) that has prepared the prescription shown in table 24～27.The topical composition of embodiment 3-11～3-32, the percutaneous absorbability of blended physiologically active ingredient all good.

Table 24

g/100g	Embodiment 3-11	Embodiment 3-12	Embodiment 3-13
g/100g	Embodiment 3-11	Embodiment 3-12	Embodiment 3-13	Hydrogenated soya phosphatide matter ^*	5	1	10
Ascorbic acid	10	10	5	Hydrogenated soya phosphatide matter ^*	5	1	10
Ascorbic acid	10	10	5	Ethoxydiglycol	43	43	25
Oleyl amine	1	0.5	1	Ethoxydiglycol	43	43	25
Oleyl amine	1	0.5	1	1,3 butylene glycol	-	-	18
Water purification	Surplus	Surplus	Surplus	1,3 butylene glycol	-	-	18

^*SLP-PC92H (iodine number is below 45); Tsuji System oil society makes

Table 25

g/100g	Embodiment 3-14	Embodiment 3-15	Embodiment 3-16	Embodiment 3-17	Embodiment 3-18	Embodiment 3-19
g/100g	Embodiment 3-14	Embodiment 3-15	Embodiment 3-16	Embodiment 3-17	Embodiment 3-18	Embodiment 3-19	Hydrogenated soya phosphatide matter ※ 1	4	5	5	-	1	5
Hydrogenated soya phosphatide matter ※ 2	-	-	-	4	0.1	-	Hydrogenated soya phosphatide matter ※ 1	4	5	5	-	1	5
Hydrogenated soya phosphatide matter ※ 2	-	-	-	4	0.1	-	Ethoxydiglycol	3	40	22	6.5	5	6
The retinol cetylate	0.1	0.1	0.1	0.1	-	-	Ethoxydiglycol	3	40	22	6.5	5	6
The retinol cetylate	0.1	0.1	0.1	0.1	-	-	D-δ-Wei A gives birth to alcohol ester	-	-	-	-	0.25	0.5
VC-IP	-	-	-	-	1	1	D-δ-Wei A gives birth to alcohol ester	-	-	-	-	0.25	0.5
VC-IP	-	-	-	-	1	1	Three 2 ethyl hexanoic acid glyceride	-	-	5	10	-	-
Three (capryl/capric acid) glyceride	-	-	-	-	2.25	4.5	Three 2 ethyl hexanoic acid glyceride	-	-	5	10	-	-
Three (capryl/capric acid) glyceride	-	-	-	-	2.25	4.5	Dibutylene glycol	-	-	-	-	-	39
1,3 butylene glycol	10	-	-	10	40	-	Dibutylene glycol	-	-	-	-	-	39
1,3 butylene glycol	10	-	-	10	40	-	Glycerol	-	-	5	-	-	-
(the copolymer of third rare acyl dimethyl taurine ammonium/VP)	-	-	-	-	1	1	Glycerol	-	-	5	-	-	-
	-	-	-	-	1	1	CVP Carbopol ETD2050	0.5	0.5	0.5	0.5	-	-
Triethanolamine	In right amount	In right amount	In right amount	In right amount	-	-	CVP Carbopol ETD2050	0.5	0.5	0.5	0.5	-	-
Triethanolamine	In right amount	In right amount	In right amount	In right amount	-	-	Water purification	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus

※ 1 SLP-PC92H (iodine number is below 45); Tsuji System oil society makes

※ 2 レシノ, one Le S-10E (iodine number is below 10); Daylight ケミカ Le ズ society makes

Table 26

g/100g	Embodiment 3-20	Embodiment 3-21	Embodiment 3-22	Embodiment 3-23	Embodiment 3-24
g/100g	Embodiment 3-20	Embodiment 3-21	Embodiment 3-22	Embodiment 3-23	Embodiment 3-24	Soybean phospholipid matter ※ 1	8	8	4	-	-
Hydrogenated soya phosphatide matter ※ 2	-	-	-	10	-	Soybean phospholipid matter ※ 1	8	8	4	-	-
Hydrogenated soya phosphatide matter ※ 2	-	-	-	10	-	Hydrogenated soya phosphatide matter ※ 3	-	-	-	-	0.5
Ethoxydiglycol	30	6	18	68	10	Hydrogenated soya phosphatide matter ※ 3	-	-	-	-	0.5
Ethoxydiglycol	30	6	18	68	10	Caffeine	2	2	1	-	-
Theophylline	-	-	-	1	-	Caffeine	2	2	1	-	-
Theophylline	-	-	-	1	-	Theobromine	-	-	-	-	1
1,3 butylene glycol	-	10	-	-	-	Theobromine	-	-	-	-	1
1,3 butylene glycol	-	10	-	-	-	CVP Carbopol ETD2050	0.5	0.5	0.5	0.5	0.5
Triethanolamine	In right amount	In right amount	In right amount	In right amount	In right amount	CVP Carbopol ETD2050	0.5	0.5	0.5	0.5	0.5
Triethanolamine	In right amount	In right amount	In right amount	In right amount	In right amount	Water purification	Surplus	Surplus	Surplus	Surplus	Surplus

※ 1 ベイシス LS-60H (iodine number is below 10); Day, clear オイリオ society made

※ 2 レシノ, one Le S-10E (iodine number is below 1 0); Daylight ケミカ Le ズ society makes

※ 3 SLP-PC92H (iodine number is below 45); Tsuji System oil society makes

Table 27

g/100g	Embodiment 3-25	Embodiment 3-26	Embodiment 3-27	Embodiment 3-28	Embodiment 3-29	Embodiment 3-30	Embodiment 3-31	Embodiment 3-32
g/100g	Embodiment 3-25	Embodiment 3-26	Embodiment 3-27	Embodiment 3-28	Embodiment 3-29	Embodiment 3-30	Embodiment 3-31	Embodiment 3-32	Hydrogenated soya phosphatide matter ※ 1	5	-	2.5	3	-	1	-	-
Hydrogenated soya phosphatide matter ※ 2	-	-	-	-	0.1	-	-	5	Hydrogenated soya phosphatide matter ※ 1	5	-	2.5	3	-	1	-	-
Hydrogenated soya phosphatide matter ※ 2	-	-	-	-	0.1	-	-	5	Soybean phospholipid matter ※ 3	-	1	-	-	-	-	2	-
Ethoxydiglycol	15	65	20	18	9	60	13	70	Soybean phospholipid matter ※ 3	-	1	-	-	-	-	2	-
Ethoxydiglycol	15	65	20	18	9	60	13	70	The retinol cetylate	0.1	-	-	-	-	-	-	-
Tretinoin	-	0.005	-	-	-	-	-	-	The retinol cetylate	0.1	-	-	-	-	-	-	-
Tretinoin	-	0.005	-	-	-	-	-	-	Retinol	-	-	0.2	-	-	-	-	-
D-δ-Wei A gives birth to alcohol ester	-	-	-	0.1	-	-	-	-	Retinol	-	-	0.2	-	-	-	-	-
D-δ-Wei A gives birth to alcohol ester	-	-	-	0.1	-	-	-	-	Retinyl acetate	-	-	-	-	0.05	-	-	-
Ascorbic acid	-	-	-	-	-	20	-	-	Retinyl acetate	-	-	-	-	0.05	-	-	-
Ascorbic acid	-	-	-	-	-	20	-	-	Ascorbate glucoside	-	-	-	-	-	-	3	-
VC-IP	-	-	-	-	-	-	-	10	Ascorbate glucoside	-	-	-	-	-	-	3	-
VC-IP	-	-	-	-	-	-	-	10	CVP Carbopol ETD2050	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Triethanolamine	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	CVP Carbopol ETD2050	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Triethanolamine	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	Water purification	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus

※ 1 SLP-PC92H (iodine number is below 45); Tsuji System oil society makes

※ 3 ベイシス LS-60H (iodine number is below 1 0); Day, clear オイリオ society made

Test routine 3-7

According to the prescription shown in the table 28, the preparation topical composition.Specifically, phospholipid, coenzyme Q10, low diol ether, three 2 ethyl hexanoic acid glyceride and the polyhydric alcohol with ormal weight dissolves the water purification that mixing is heated in addition in the lysate that obtains.And then in the mixed liquor that obtains, quantitative other compositions of hybrid regulatory have prepared the topical composition (lipid build) of embodiment 3-33～3-35 and comparative example 3-9.For each topical composition, utilize identical method with above-mentioned test example 1-7, estimated the percutaneous absorbability of coenzyme Q10.Its result is shown in table 28.

Table 28

g/100g	Embodiment 3-33	Embodiment 3-34	Embodiment 3-35	Comparative example-39
g/100g	Embodiment 3-33	Embodiment 3-34	Embodiment 3-35	Comparative example-39	Partially hydrogenated soybean lecithin ^*1	1	-	-	-
Hydrogenated soy phosphatidyl choline ^*2	-	1	-	1	Partially hydrogenated soybean lecithin ^*1	1	-	-	-
Hydrogenated soy phosphatidyl choline ^*2	-	1	-	1	Soybean lecithin ^*3	-	-	1	-
Ethoxydiglycol	69	69	69	-	Soybean lecithin ^*3	-	-	1	-
Ethoxydiglycol	69	69	69	-	Coenzyme Q10	0.03	0.03	0.03	0.03
Glycerol	-	-	-	69	Coenzyme Q10	0.03	0.03	0.03	0.03
Glycerol	-	-	-	69	Three 2 ethyl hexanoic acid glyceride	2.97	2.97	2.97	2.97
Water purification	In right amount	In right amount	In right amount	In right amount	Three 2 ethyl hexanoic acid glyceride	2.97	2.97	2.97	2.97
Water purification	In right amount	In right amount	In right amount	In right amount	Hold allowance (μ g/cm ²)	2.80	1.58	3.71	0.44

※ 1:SLP-PC92H (iodine number is below 45); Tsuji System oil society makes

※ 2: レシノ one Le S-10E (iodine number is below 10); Daylight ケミカ Le ズ society makes

※ 3:SLP-PC70; Tsuji System oil society makes

Compare with the topical composition of the comparative example 3-9 that has mixed glycerol, mixed the topical composition of the embodiment 3-33～3-35 of ethoxydiglycol, in the skin of its coenzyme Q10 to hold that allowance significantly improves be 3.6～8.4 times.In addition, can confirm the lecithin that hydrogenation degree is low, further improve the percutaneous absorbability of coenzyme Q10.In addition, isoprene unit is that (Coenzyme Qq6～Q9) and isoprene unit are that 10 coenzyme Q10 rerum natura is very similar, can predict to have roughly the same movement in Transdermal absorption for 6～9 ubiquinone.

Test routine 3-8

Topical composition (the embodiment 3-36～3-49) that has prepared the prescription shown in table 29 and 30.The topical composition of embodiment 3-36～3-49, the percutaneous absorbability of blended physiologically active ingredient all good.

Table 29

g/100g	Embodiment 3-36	Embodiment 3-37	Embodiment 3-38
g/100g	Embodiment 3-36	Embodiment 3-37	Embodiment 3-38	Hydrogenated soya phosphatide matter ^*1	1	1	1
Hydrogenated soya phosphatide matter ^*2	-	-	1.5	Hydrogenated soya phosphatide matter ^*1	1	1	1
Hydrogenated soya phosphatide matter ^*2	-	-	1.5	Ethoxydiglycol	5	6	5
Coenzyme Q10	0.03	0.03	0.03	Ethoxydiglycol	5	6	5
Coenzyme Q10	0.03	0.03	0.03	Vitamin A oil	-	-	0.15
1,3 butylene glycol	40	-	10	Vitamin A oil	-	-	0.15
1,3 butylene glycol	40	-	10	Dipropylene glycol	-	39	10
Three 2 ethyl hexanoic acid glyceride	-	-	10	Dipropylene glycol	-	39	10
Three 2 ethyl hexanoic acid glyceride	-	-	10	(the copolymer of third rare acyl dimethyl taurine ammonium/VP)	1	1	-
Acrylic acid/alkyl methacrylate copolymer	-	-	1		1	1	-
Acrylic acid/alkyl methacrylate copolymer	-	-	1	Triethanolamine	-	-	0.1
Water purification	Surplus	Surplus	Surplus	Triethanolamine	-	-	0.1

* 1 SLP-PC92H (iodine number is below 45); Tsuji System oil society makes

* 2 レシノ, one Le S-10E (iodine number is below 10); Daylight ケミカ Le ズ society makes

Table 30

g/100g	Embodiment 3-39	Embodiment 3-40	Embodiment 3-41	Embodiment 3-42	Embodiment 3-43	Embodiment 3-44	Embodiment 3-45	Embodiment 3-46	Embodiment 3-47	Embodiment 3-48	Embodiment 3-49
g/100g	Embodiment 3-39	Embodiment 3-40	Embodiment 3-41	Embodiment 3-42	Embodiment 3-43	Embodiment 3-44	Embodiment 3-45	Embodiment 3-46	Embodiment 3-47	Embodiment 3-48	Embodiment 3-49	Hydrogenated soya phosphatide matter ※ 1	-	-	2.5	-	0.1	-	-	-	-	10	-
Hydrogenated soya phosphatide matter ※ 2	5	-	-	3	-	1	-	-	4	-	0.5	Hydrogenated soya phosphatide matter ※ 1	-	-	2.5	-	0.1	-	-	-	-	10	-
Hydrogenated soya phosphatide matter ※ 2	5	-	-	3	-	1	-	-	4	-	0.5	Soybean phospholipid matter ※ 3	-	1	-	-	-	-	2	0.5	-	-	-
Coenzyme Qq6	0.03	0.3	3	-	-	-	-	-	-	-	-	Soybean phospholipid matter ※ 3	-	1	-	-	-	-	2	0.5	-	-	-
Coenzyme Qq6	0.03	0.3	3	-	-	-	-	-	-	-	-	Ubiquinone 7	-	0.03	0.3	3	-	-	-	-	-	-	-
Ubiquinone 8	-	-	-	0.03	0.3	3	-	-	-	-	-	Ubiquinone 7	-	0.03	0.3	3	-	-	-	-	-	-	-
Ubiquinone 8	-	-	-	0.03	0.3	3	-	-	-	-	-	Q9	-	-	-	-	0.03	0.3	3	-	-	-	-
Coenzyme Q10	-	-	-	-	-	-	-	0.01	0.3	1	3	Q9	-	-	-	-	0.03	0.3	3	-	-	-	-
Coenzyme Q10	-	-	-	-	-	-	-	0.01	0.3	1	3	Three 2 ethyl hexanoic acid glyceride	3	3	10	10	3	10	10	3	3	3	10
Ethoxydiglycol	15	65	20	18	9	60	13	70	18	68	10	Three 2 ethyl hexanoic acid glyceride	3	3	10	10	3	10	10	3	3	3	10
Ethoxydiglycol	15	65	20	18	9	60	13	70	18	68	10	CVP Carbopol ETD2050	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Triethanolamine	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	CVP Carbopol ETD2050	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Triethanolamine	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	In right amount	Water purification	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus	Surplus

※ 1 レシノ, one Le S-10E (iodine number is below 10); Daylight ケミカ Le ズ society makes

※ 2 SLP-PC92H (iodine number is below 45); Tsuji System oil society makes

※ 3 ベイシス LS-60H (iodine number is below 10); Day, clear オイリオ society made

Industrial applicibility

According to topical composition of the present invention, by containing (i) Phospholipids and 22 % by weight above (ii) list or low diol ether, can improve the Transdermal absorption of physiologically active ingredient.

In addition, according to topical composition of the present invention, (i) Phospholipids by containing 0.01～8 % by weight and (ii) list or the low diol ether of 0.01～6.5 % by weight, Transdermal absorption that also can the Effective Raise physiologically active ingredient.

And then, according to topical composition of the present invention, by containing (i) Phospholipids and (ii) list or low diol ether, can improve the percutaneous absorbability that (iv) is selected from least a physiologically active ingredient in hyaluronic acid, derivatives of hyaluronic acids, vitamin A, vitamin A derivative, vitamin C, specific vitamin C derivatives, xanthine derivative, ubiquinone and their salt. Especially, topical composition of the present invention has for the hyaluronic acid that is difficult to absorb skin inside, also can give the advantage of good percutaneous absorbability.

Claims

1. a topical composition is characterized in that, contains (i) phospholipid and (ii) list or low diol ether, with respect to the total amount of topical composition, contains (ii) list or low diol ether with the ratio more than the 22 weight %.

2. topical composition as claimed in claim 1 also contains (iii) physiologically active ingredient.

3. topical composition as claimed in claim 1, wherein, (ii) list or low diol ether are the chemical compound of following general formula (1) expression,

R ₁-O(A-O) _n-R ₂ (1)

In the formula, R ₁And R ₂Identical or different, be the alkyl of carbon number 1～6, thiazolinyl, aryl, acetyl group or the hydrogen atom of carbon number 2～6, wherein, R ₁And R ₂At least one side be the alkyl of carbon number 1～6, the thiazolinyl or the aryl of carbon number 2～6; A represents the alkylidene of carbon number 2～4; N represents 1～4 integer.

4. topical composition as claimed in claim 1 with respect to the total amount of topical composition, contains (i) phospholipid with the ratio of 0.01～15 weight %.

5. a topical composition is characterized in that, with respect to the total amount of topical composition, contains (i) phospholipid of 0.01～8 weight % and (ii) list or the low diol ether of 0.01～6.5 weight %.

6. topical composition as claimed in claim 5 also contains (iii) physiologically active ingredient.

7. topical composition as claimed in claim 5, wherein, (ii) list or low diol ether are the chemical compound with following general formula (1) expression,

R ₁-O(A-O) _n-R ₂ (1)

8. a topical composition contains

(i) phospholipid,

(ii) list or low diol ether, and

(iv) be selected from least a physiologically active ingredient in salt, hydroascorbic acid, ascorbate glucoside, ascorbyl stearate, L-Vitamin C dipalmitate and/or VC-IP, xanthine derivative, ubiquinone and their salt of hyaluronic acid, vitamin A, vitamin A derivative, ascorbic acid, ascorbic acid.

9. topical composition as claimed in claim 8, wherein, (ii) list or low diol ether are the chemical compound with following general formula (1) expression,

R ₁-O(A-O) _n-R ₂ (1)

10. topical composition as claimed in claim 8, wherein, (iv) physiologically active ingredient is hyaluronic acid and/or its salt.

11. topical composition as claimed in claim 8, wherein, (iv) physiologically active ingredient is to be selected from least a in retinol, retinyl acetate, retinol cetylate, retinal, tretinoin, tretinoin methyl ester, tretinoin ethyl ester, tretinoin retinol ester, vitamin A fatty acid ester, d-δ-Wei A fertility alcohol ester, α-Wei A fertility alcohol ester and β-Wei A fertility alcohol ester.

12. topical composition as claimed in claim 8, wherein, (iv) physiologically active ingredient is at least a in salt, hydroascorbic acid, ascorbate glucoside, ascorbyl stearate, L-Vitamin C dipalmitate and the VC-IP that is selected from ascorbic acid, ascorbic acid.

13. topical composition as claimed in claim 8, wherein, (iv) physiologically active ingredient is at least a xanthine derivative that is selected from caffeine, aminophylline, theophylline, Oxtriphylline, glycerol dish alkali, two isobutyl aminobenzoic acyl-oxygen propyl group theophylline, theobromine, diprophylline, proxyphylline and the pentoxifylline.

14. topical composition as claimed in claim 8, wherein, (iv) physiologically active ingredient is at least a ubiquinone that is selected among Coenzyme Qq6, Q7, Q8, Q9 and the Q10.

15. contain (i) phospholipid and (ii) list or low diol ether, total amount with respect to topical composition, contain the topical composition of (ii) list or low diol ether with the ratio more than the 22 weight %, improve application in the preparation of the (iii) Transdermal absorption of physiologically active ingredient in manufacturing.

16. total amount with respect to topical composition, (i) phospholipid and the (ii) list of 0.01～6.5 weight % or the topical composition of low diol ether that contain 0.01～8 weight % improve application in the preparation of the (iii) Transdermal absorption of physiologically active ingredient in manufacturing.

17. contain (i) phospholipid and the (ii) topical composition of list or low diol ether, the application in the preparation of making the Transdermal absorption of improving at least a physiologically active ingredient in salt, hydroascorbic acid, ascorbate glucoside, ascorbyl stearate, L-Vitamin C dipalmitate and/or VC-IP, xanthine derivative, ubiquinone and their salt that (iv) is selected from hyaluronic acid, vitamin A, vitamin A derivative, ascorbic acid, ascorbic acid.